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Ovarian cancer is the fifth leading cause of cancer related death in females and current 
clinical treatments have low patient survival rates. Nanoparticle drug delivery has been promoted 
as an effective therapy, however very few nanoformulations are translated from the lab to the clinic. 
This absence of successful nanoparticles is partially due to: 1) a lack of understanding of how 
nanoparticle properties impact in vivo biodistribution, 2) nanoparticle design which does not 
consider the multi-faceted tumor microenvironment (TME), and 3) reliance on chemotherapeutics 
which cause harsh side effects. My work addressed these shortcomings by designing polymer 
nanoparticles for improving ovarian cancer treatments.  
The first aim was to develop wettability engendered templated self-assembly (WETS), a 
polymer particle fabrication method. This technique can produce monodisperse, spherical and non-
spherical multiphasic particles in a range of 25 nm to 150 µm with up to 7 phases. The size, planar 
geometry and composition of each phase can be independently altered in non-spherical particles 
which can be reconfigured into spherical particles. WETS is the first technique which has clearly 
defined predictive models that allow for the fabrication of extremely varied particles with a single 
method. With continued work focused on the scale up of WETS, this method could enable the 
undertaking of a systematic study of particle properties in vivo. A survey of particle biodistribution 
based on size, shape and composition would improve the understanding of nanoparticle drug 
delivery. Additionally, ideal particle properties for cancer therapies could be identified, thus 





The second aim focused on developing a co-delivery nanoparticle therapy that addresses 
the supportive nature of non-cancerous mesenchymal stem cells (MSC) in the TME. MSC have 
been shown to increase cancer stem cells (CSC) chemoresistance and metastasis, and this effect is 
generally ignored in the design of nanoparticles for drug delivery. Polymer nanoparticles 
fabricated with electrospraying were demonstrated to encapsulate both paclitaxel and sunitinib 
with a diameter of 150-200 nm. Delivery of sunitinib as a free drug was shown to disrupt CSC 
stemness and migration due to MSC co-culture, and co-delivery of sunitinib and paclitaxel was 
more effective in causing CSC death. This identifies paclitaxel and sunitinib as a possible co-
delivery nanoparticle therapy for future studies.  
Finally, the third aim investigated α-terpineol (αT), one of the active components of tea 
tree oil, as a chemotherapeutic for ovarian cancer. αT was found to be more specific in killing 
ovarian cancer cells as opposed to non-cancerous cells and was able to be encapsulated within an 
electrosprayed polymer nanoparticle (150-200 nm). Continued work in developing an αT-
conjugated polymer could lead to the fabrication of a slow-release formulation with a higher initial 
αT loading which is hypothesized to be more effective.   
In summary, my PhD work has created innovative polymer nanoparticle technologies and 
therapeutic approaches to kill ovarian cancer cells and improve cure rates. The unique and highly 
versatile polymer particle fabrication method, WETS, was developed and can contribute 
extensively to the understanding of nanoparticle behavior in vivo. Additionally, investigation into 
the combination treatment of paclitaxel and sunitinib, as well as αT was carried out which can 
provide insight to future ovarian cancer therapies. This work reflects the integration of concepts 






Chapter 1: Introduction 
1.1 Introduction to Ovarian Cancer 
Cancer is the second leading cause of death in the United States with an estimated 1.8 
million new cases diagnosed in 20204. For females, ovarian cancer is one of the most deadly due 
to late stage detection making it the fifth leading cause of cancer related deaths in females4,5. 
Additionally, a sub-population of cancerous cells, cancer stem cells (CSC) have been linked to the 
high mortality rate in ovarian cancer due to increased tumor growth, chemoresistance and 
metastasis6–8. However, these CSC do not act alone and are highly influenced by other cell types 
within the ovarian cancer microenvironment such as macrophages, mesenchymal stem cells 
(MSC) and fibroblasts among many others3,9–12. Macrophages have been linked to angiogenesis, 
metastasis and enabling CSC immune escape13. Cancer-associated fibroblasts have been shown to 
increase tumor growth, inflammation, chemoresistance and the prevalence of CSC through the 
secretion of various paracrine factors11,14. MSC have recently been implicated in increased 
chemoresistance, proliferation and invasion of ovarian CSC15–18.  
Assistance from these non-cancerous cells leads to the dissemination of the cancer into the 
peritoneal cavity which renders surgical removal of cancerous growths much more difficult. 
Platinum based chemotherapy is usually paired with surgical removal to treat remaining cells and 
metastasized growths, however this treatment method has a response rate of only ~65% with a 
median overall survival of ~2-5 years. This low response rate is due to the high frequency of 





become extremely ill during treatment and report feelings of depression and stress due to the fear 
of reoccurrence, the pain resulting from surgery and chemotherapy, and for younger patients, 
developed infertility21. This highlights the need for additional and more effective treatment 
methods for ovarian cancer in the clinic which target CSC and their microenvironment-conferred 
malignant properties, as well as treatments that have gentler side effects on the physical and mental 
well-being of patients.   
1.2 Nanoparticle Drug Delivery as a Cancer Therapy 
Nanoparticle drug delivery for cancer therapy has been promised to be next breakthrough 
for many years since the inception of Paul Ehrlich’s ‘magic bullet’ and Matsumura and Maeda’s 
publication identifying the enhanced permeability and retention (EPR) effect in cancers22,23. 
Nanoparticle passive targeting with the EPR effect allows for a higher accumulation of drug at the 
tumor site, and less elsewhere in the body as nanoparticles will naturally extravasate at the tumor 
site due to the leaky vasculature and then remain in the tumor area due to poor lymphatic 
drainage24,25. Functionalizing the nanoparticle surface with targeting agents is a form of active 
targeting that is used in conjunction with the EPR effect to keep extravasated nanoparticles from 
being cleared, as well as promoting nanoparticle internalization by the targeted cells26. As more 
drug will naturally be directed to the tumor site using nanoparticles instead of systemic delivery, 
a higher overall dose can be administered without increasing the severity of the side effects. 
Additionally, nanoparticle drug delivery also increases the ability to deliver hydrophobic or more 
fragile drugs, such as siRNA, as the nanoparticles have a prolonged circulation time as well as 
protecting the drug it is encapsulating from being absorbed or metabolized at a non-specific site27. 
However, despite many publications detailing the benefits of nanoparticle drug delivery, this 





the U.S. Food and Drug Administration (FDA) since 1992 due to many challenges in translation 
from laboratory to the clinic28,29.  
Some of the challenges that have prevented the development of effective nanoparticle 
therapies have been extensively discussed30, but are summarized here. Continued research has 
shown that the EPR effect is not present in most human cancers and that while encapsulating a 
drug in a nanoparticle does increase delivery to the target site, the increase is very small compared 
to the amount of drug that still accumulates in off-target locations31,32. Additionally, detailed 
understanding of how nanoparticle size, shape and chemistry impacts in vivo biodistribution is 
lacking due to a previous reliance on the EPR effect to overcome differences in nanoparticle 
properties33,34. There is also little development in nanoparticle design which is able to increase 
nanoparticle penetration into solid tumors once the nanoparticles reach the tumor mass, lowering 
the effectiveness of nanoparticles even further30,35.  
1.3 Thesis Overview and Impact  
In this work, polymer nanoparticle systems were designed in order to address some of the 
short comings of current ovarian cancer therapies through nanoparticle drug delivery. Chapter 2 
focuses on the development of a new polymer particle fabrication method, wettability engendered 
templated self-assembly (WETS). This method is the first that can produce monodisperse, 
spherical and non-spherical multiphasic particles with independent control of the nanoparticle’s 
size, shape, and chemistry as well as that of each individual phase. Predictive models for both non-
spherical and spherical particles have been defined and enable the fabrication of particles with 
specific sizes, shapes, chemistries, and phase morphologies. Synthesis of systematically varied 
particles, produced with a single method, could enable the undertaking of a detailed study of 





of nanoparticle drug delivery as particle properties could be directly linked to circulation rates, 
biodistribution and tumor accumulation. With this knowledge, identification of ideal particle 
properties could overcome the lack of the EPR effect seen in human cancer, increase in vivo 
nanoparticle uptake and improve nanoparticle efficacy overall.  
Chapter 3 investigates the fabrication and design of electrosprayed polymer nanoparticles 
for the co-delivery of paclitaxel, an antimicrotubule-chemotherapeutic, and sunitinib, a tyrosine 
kinase inhibitor.  This co-delivery nanoparticle seeks to leverage the role of CSC-MSC interactions 
in CSC chemoresistance to improve toxicity of paclitaxel to CSC. Electrosprayed nanoparticles 
with diameters of 150-200 nm successfully encapsulated paclitaxel and sunitinib, demonstrating 
the feasibility of co-delivery electrospray nanoparticles to target CSC-MSC interactions and 
improve clinical outcomes. This potential was further evaluated through co-delivery of the free 
drugs using a 3D hanging drop model to study how this treatment would impact CSC 
chemoresistance, migration and stemness.  
Chapter 4 focuses on studying α-terpineol, an active component of tea tree oil, as an 
alternative chemotherapeutic. α-terpineol delivered without modification was found to be more 
toxic to ovarian cancer cells than non-cancerous cells and can be encapsulated in electrosprayed 
polymer nanoparticles with diameters of 150-200 nm. It is hypothesized that α-terpineol has the 
potential to serve as a cancer therapy with fewer negative side effects than current ovarian cancer 
treatments. 
Taken together, this work seeks to improve nanoparticle drug delivery through 3 methods: 
1) by identifying polymer nanoparticles that are more effective in reaching the tumor site by 
developing a fabrication method to study particle behavior in vivo, 2) by investigating a co-delivery 





microenvironment, and 3) studying an alternative chemotherapeutic which has the potential to 








Chapter 2: Wettability Engendered Templated Self-Assembly (WETS) for the 
Fabrication of Multiphasic, Spherical and Non-spherical Polymer Particles 
2.1 Introduction 
Nanoparticles have been developed for many medical uses such as drug delivery, imaging, 
tissue engineering and regenerative medicine36–39. However, despite the many benefits of these 
particles, fabrication of monodisperse particle samples, or more complex particles such as non-
spherical, stimuli-responsive, or multiphasic particles has been difficult. Multiphasic particles 
have many advantages in medical applications, including: 1) a separate compartment for each 
payload which avoids negative interactions and allows for independent release rates, 2) the means 
to encapsulate payloads with different solubilities, 3) the ability to combine diagnostic and 
therapeutic agents, 4) multiple surface chemistries for additional functionality and 5) orientation 
directed self-assembly1,40–49. Stimuli-responsive particles are projected to have a significant impact 
on a wide range of applications including self-assembled structures50–52,  biosensors/actuators53–56 
and drug delivery40,57–59. For drug delivery, specifically, conflicting particle requirements, such as 
a spherical versus non-spherical shape, are needed for overcoming different biological hurdles, 
and an in situ reconfiguration could potentially increase nanoparticle targeting58–62. Finally, 
polydisperse samples will have varying biodistributions, drug release profiles and degradation 
rates which can cloud either definitive results or the effectiveness of a medical treatment making 





Combining several of these challenging designs into one fabrication method also increases 
the difficulty, and current fabrication methods have yet to include them all in a fully operational 
manner. Electrospray and emulsion methods can fabricate multiphasic particles at a higher yield 
and can produce non-spherical particles, but can be challenging to produce small (<100 nm) and 
monodisperse samples46,65–68. Microfluidic devices can easily produce monodisperse samples and 
multiphasic particles but increasing the yield and maintaining monodispersity is difficult as it 
requires many parallel devices operating in sync69,70. Additionally, microfluidic devices can 
fabricate non-spherical particles, however stop-flow lithography and cross-linkable polymers must 
be employed which slows production and limits particle chemistry71. A unique method, Particle 
Replication in Non-wetting Templates (PRINT), uses a mold to create non-spherical, 
monodisperse particles and has been scaled up to support in vivo studies72,73. However, methods 
to create multiphasic PRINT particles have not been scaled beyond a proof of practice and 
spherical particles cannot be fabricated due to the mold requiring at least one flat face74,75. 
Application of nanoparticles has also been difficult as, despite thousands of publications 
detailing improvements in nanoparticle design, there has not been an increase in nanoparticle 
delivery to target locations or in clinical translation28,29,34,35. One difficulty lies in the scale up 
production of nanoparticles from the laboratory to clinical trials. Another challenge is the 
physiological barriers that nanoparticles face in vivo, especially as the enhanced permeability and 
retention (EPR) effect is not present in most human cancers32,76,77. Most nanoparticle designs for 
the past 30 years have relied on the EPR effect to assist in targeting, and only recently have 
investigations been made into how nanoparticle properties impact in vivo behaviors such as 
circulation time and accumulation locations. A systematic study of nanoparticle properties in vivo 





The nanoparticle fabrication method must be able to produce monodisperse particles, spherical 
and non-spherical particles in a range of sizes, and multiphasic particles with independent control 
of all characteristics. If the nanoparticles cannot be produced with the same method, or independent 
control of nanoparticle properties cannot be maintained, then it may be difficult to make definite 
conclusions. This has led to the development of the Wettability Engendered Templated Self-
assembly (WETS) particle fabrication method which was first demonstrated on the microscale to 
fully develop and understand the process before investigations into reducing particle size and 
increasing production were initiated.  
2.2 Results and Discussion 
2.2.1 Non-spherical Microparticle Fabrication 
The WETS method (Figure 2.1A) uses patterned wettability templates in order to fabricate 
non-spherical microparticle assemblies on its surface. The patterned wettability templates have a 
fluorinated non-wetting background with a low contact angle hysteresis which allows liquids to 
recede from the surface. The wettable portion of the template forms discrete domains of high 
energy titanium dioxide (TiO2) which has a high contact angle hysteresis and prevents liquids from 
receding. When this patterned substrate is dip-coated into a polymer solution, the polymer solution 
will self-assemble in the wettable domains, filling the size and shape of the domain, and will recede 
from the background creating discrete droplets on the surface. Upon evaporation of the solvent, 
the polymer will take the size and shape of the wettable domain creating a non-spherical polymer 
layer. The first polymer layer deposited is the release layer, and it will be dissolved to release the 
particle assemblies from the substrate once the particle is complete. Subsequent polymer layers 
are deposited by dip-coating the substrate in sequential polymer solutions and each layer forms a 





background and thus form directly on top of the previous layer (Figure 2.1B-D). Once all desired 
layers have been dip-coated, the release layer is dissolved and the particles harvested, after which 
the substrate can be reused. A final reconfiguration step can be taken to form spherical particles 
from the non-spherical particles that are collected from the substrate. As the polymer solution 
completely fills the wettable domain, the size and shape of the particles is determined by the 
dimensions of this domain. This allows for a very high degree of control of the lateral dimensions 
of the non-spherical particle and the fabrication of virtually any desired size and shape (Figure 
2.1E-H).  
 
Figure 2.1: WETS fabrication method schematic and non-spherical particle assemblies 
A) Schematic depicting the fabrication of biphasic particles using the WETS method. Optical (top) 
and fluorescent (middle and bottom) microscopy images of the B) release layer, C) first polymer 
layer and the D) second polymer layer. Fluorescent microscopy images of non-spherical particle 
assemblies of various sizes and shapes including E) 50 μm triangles, F) 50 μm squares, G) 10 μm 






WETS substrates can also be used to fabricate charged, multiphasic polymeric particles by 
adding polyelectrolyte bilayers to a polymer core. Fabrication of charged particles begins with the 
same method as mentioned previously: dip-coating of the release layer and then the first polymer 
layer which serves as the polymer core. After this, the substrate is dip-coated in a polyelectrolyte 
solution and followed by a water wash. Next the oppositely charged polyelectrolyte is dip-coated 
and followed by a water wash which then creates one bilayer on the surface of the polymer core 
(Figure 2.2A). Dip-coating can alternate between the two polyelectrolyte solutions as many times 
as desired to build up the thickness of the charged phase which can be measured by atomic force 
microscopy (AFM) (Figure 2.2B-F) and seen with scanning electron microscopy (SEM) (Figure 
2.2G, H). By altering the charge of the polymer core and the final layer of the polyelectrolyte 
bilayer, particles with different surface charges can be fabricated, and highly charged payloads, 






Figure 2.2: Charged, multiphasic particles can be fabricated using the WETS method 
A) Schematic of the WETS method incorporating the dip-coating and water washes of 
polyelectrolyte solutions. AFM scans showing the particle thickness after dip-coating the B) 
release layer, C) polymer core and D) 3 polyelectrolyte bilayers. E) Compilation of the height 
profiles from (B), (C) and (D). F) Plot of the linear increase in bilayer phase thickness as the 
number of bilayers increases as measured with AFM. G) Schematic of the cross section of a 





Zeta potential measurements of released particles based on the final layer deposited during dip-
coating.  
 
Lateral dimensions of particles fabricated with WETS are controlled by the size and shape 
of the wettable domain on the substrate. Particle thickness can be measured with AFM, and each 
added layer can be measured individually knowing that the AFM height will be the combined 
thickness of all the layers previously deposited and the most recent one (Figure 2.3A-G). The 
thickness of the polymer layer deposited, t, is controlled by the dip-coating parameters and can be 
modeled with Equation 2.1, where  is the polymer volume fraction of the polymer solution, W is 
the width of the wettable domain, μ is the polymer solution viscosity, V is the dip-coating 
withdrawal rate, γLV is the surface tension of the polymer solution and k is a linear constant (Figure 
2.3H).  





    
 
As previously seen in Figure 2.2E and also seen in the SEM cross-section in Figure 2.3I, 
the polymer layers take the shape of a spherical cap and the thickness of the particles is measured 
in the center which is usually the highest point. The total particle thickness will be the sum of all 
the layers which comprise the particle. The ability to individually control each layer’s chemistry, 
composition and thickness will allow for exquisite control over the design of multiphasic particles, 
and in turn help study the impact of each parameter on in vivo behavior and effectiveness (Figure 
2.3J, K). As the lateral dimensions are controlled by the dimensions of the wettable domain, the 






Figure 2.3: The thickness of each polymer layer in a multiphasic WETS particle is individually 
controlled by the dip-coating parameters of that layer 
AFM height scans of particle assemblies as the A) release, B) first polymer and C) second polymer 
layers are deposited. Thicknesses measured when more than one layer is present is the sum of all 
previous layers and the most recent. AFM thickness measurements of various particles including 
a D) 50 μm square, E) 50 μm hexagon, F) 10 μm circle and G) 3 μm circle. H) Plot showing the 
layer thickness equation for the same polymer solution but on two different wettable domain 
widths. I) SEM cross-section of a tri-phasic particle assembly showing the spherical cap 





on the substrate. J) The same particle shown in (I) but indicating the area of interest K) enlarged 
to show the three different phases and their payloads.   
 
The non-spherical, multiphasic particle assemblies are released from the substrate by 
dissolving away the release layer and are then collected for further characterization (Figure 2.4). 
The WETS substrates are then reused to fabricate another batch of particles. This subsequent batch 
of particles produced with the same substrate can be exactly the same and added to the first batch 
to increase the number of particles, or the new particles can be fabricated with different dip-coating 
parameters to adjust their properties. The wettable domain of the substrate, which dictates the 
lateral dimensions of the particle, will be the only property that limits how different the second 
batch of particles can be. Various polymers can be used to alter surface chemistry, a different 
number of phases can change which combination of cargo are loaded and the thickness of each 
phase can be adjusted to fine tune the Janus balance, or ratio of phases. Despite the range of 
purposeful differences between the batches of particles, direct comparisons between the particles 
can still be made as they will have been fabricated with the same method.  
 






SEM images of A) 150 μm block Ms, B) 50 μm hexagons, C) 50 μm squares, D) 50 μm triangles, 
E) 10 μm disks, F) 50 μm disks.  
 
2.2.2 Spherical Microparticle Reconfiguration   
Fabrication of spherical particles from non-spherical particles occurs after the non-
spherical particles have been released from the reusable WETS templates, and the particles have 
been collected in a liquid medium, generally water. The liquid medium, and thus the particles are 
then heated to a temperature above the glass transition of all the polymers comprising the particles 
and the temperature is maintained until the polymer chains have reconfigured the particle into a 
sphere. For polymers that have glass transition temperatures above 100°C, a 50% water and 50% 
glycerol solution was used as the liquid medium. Once the particle reconfiguration is complete, 
the particle solution is then returned to room temperature and the particles solidified. The liquid 
medium can then be evaporated or replaced through centrifugation pelleting. During 
reconfiguration, the non-spherical particles will begin to shrink and fold, which can be seen in 
partially reconfigured particles that have been frozen (Figure 2.5A, B, D, E). Particles maintained 
at a higher temperature for longer will continue to fold and shrink until a sphere is formed (Figure 
2.5C, F). The volume of the particle is maintained during reconfiguration, and therefore the 
diameter (ds) of the resulting spherical particle can be determined by relating the volume of a 
spherical cap (width dw and thickness t) to that of a sphere (Equation 2.2, Figure 2.5G, H).  
Equation 2.2  𝑑𝑠 = √
3
4




As seen in Figure 2.5A-F, reconfiguration is not an instantaneous process, and the time 
needed will depend on the temperature, size of the particles and the individual glass transition 






Figure 2.5: Reconfiguration of non-spherical particles to spherical particles 
SEM images of A) non-spherical, square particles before reconfiguration, B) after 6 minutes of 
reconfiguration and C) after 18 minutes of reconfiguration where the particles are now spheres. 
SEM images of D) non-spherical, triangle particles before reconfiguration, E) after 6 minutes of 
reconfiguration and F) after 18 minutes of reconfiguration where the particles are now spheres. G) 
Schematic of a non-spherical particle and the possible spherical particle resulting from 
reconfiguration. H) Plot showing how the volume of the particles are maintained during 
reconfiguration and thus the resulting spherical diameter can be predicted based on the known 
dimensions of the non-spherical particle. I) Suggested phase diagram of particle reconfiguration 






In addition to volume, particle properties are translatable during the reconfiguration from 
non-spherical to spherical. For example, the Janus balance can be maintained which is important 
for co-delivery of drugs in drug delivery applications. By adjusting the polymer volume fraction 
of the two different polymers during the dip-coating process, the Janus balance can be adjusted 
(Figure 2.6A-C). Integrity of the two different phases can also be seen post-reconfiguration. To 
understand the morphology of these multiphasic, spherical particles, individual phases were 
preferentially dissolved. Figure 2.6D, E depict an SEM image and a schematic of a biphasic 
particle with a single phase dissolved showing a concave morphology indicating that the dissolved 
phase was partially encapsulated by the other. In Figure 2.6F, attempted dissolution of a phase 
shows no change in the particle morphology suggesting that one phase is completely encapsulated 
by the other phase creating a core-shell morphology. Triphasic particles can also be reconfigured 
(Figure 2.6G), and Figure 2.6H, I depict selective dissolution of different phases indicating that 






Figure 2.6: Exploring the morphology of reconfigured, multiphasic, spherical particles 
SEM images of a biphasic PS(blue)-PLGA(red) particle with different dip-coating parameters of 
A) 80 vol% PS and 20 vol% PLGA, B) 50 vol% PS and 50 vol% PLGA, and C) 20 vol% PS and 
80 vol% PLGA to alter the resulting Janus balance. Insets (A)-(C) are fluorescent microscopy 
images of the same particles showing the maintained integrity of the different phases. Inset scale 
bar is 25 μm. D) SEM image of the particles from (A) where the PS phase has been dissolved with 
cyclohexane showing the morphology of the PLGA phase. E) Schematic of the dissolution of the 
PS phase and the remaining PLGA phase. F) SEM image of a PMMA-PS core-shell particle where 
(inset) treating with cyclohexane causes no change in the particle morphology. Inset scale bar is 
10 μm. Upper right inset is a suggested schematic of the core-shell particle. G) SEM image of a 
reconfigured triphasic particle PS(blue)-PLGA(red)-PVAc(green) with a suggested schematic in 
the upper right. H) Dissolution of the PS phase with cyclohexane of the same particles in (G). Inset 
depicts a schematic of the particles. I) Particles from (G) treated with ethanol to dissolve the PVAc 
phase. The inset depicts the morphology of the particles post-dissolution.  
 
Regardless of the starting shape of the non-spherical particle, after reconfiguration the 
shape will always be a sphere due to the minimization of the interfacial surface energies of all 
polymer-liquid (γP,L) and polymer-polymer (γP1,P2) interfaces in the system, and as γP,L is typically 





Equation 2.3, where A is the interfacial area. For a particle system with more phases, more terms 
would be required.  
Equation 2.3  𝐸 = 𝛾𝑃1𝐿𝐴𝑃1𝐿 + 𝛾𝑃1𝑃2𝐴𝑃1𝑃2 + 𝛾𝑃2𝐿𝐴𝑃2𝐿  
 
For a biphasic particle, there are three possible morphologies after reconfiguration: phase 
separated, partially encapsulated and core-shell (Figure 2.7A). Boundary conditions defined by 
γP1,P2 determine which phase is energetically favorable. For the boundary condition between a 
core-shell and a partially encapsulated particle (Figure 2.7B), it was assumed that the change in 
AP1,P2 (area of the shared interface of P1 and P2) between the two configurations is very small, and 
the change in AP1,P2 can be represented as ΔAP1,P2 = dA. Therefore, ΔAP1,L = dA, and ΔAP2,L = -dA 
and the difference in surface free energy between the two morphologies can be calculated 
(Equation 2.4), where ECS and EPE are the core-shell and partially encapsulated energies, 
respectively.  
Equation 2.4  𝐸𝐶𝑆 − 𝐸𝑃𝐸 = 𝛾𝑃1𝐿𝑑𝐴 + 𝛾𝑃1𝑃2𝑑𝐴 − 𝛾𝑃2𝐿𝑑𝐴 
 
For a stable core-shell morphology, the energy can be written as Equation 2.5.  
Equation 2.5  𝐸𝐶𝑆 − 𝐸𝑃𝐸 = 𝛾𝑃1𝐿𝑑𝐴 + 𝛾𝑃1𝑃2𝑑𝐴 − 𝛾𝑃2𝐿𝑑𝐴 < 0  
 
Where Equation 2.6 can be determined as the boundary condition for a stable core-shell 
morphology based on Equation 2.4 and Equation 2.5. 
Equation 2.6  𝛾𝑃1𝑃2 < 𝛾𝑃2𝐿 − 𝛾𝑃1𝐿  
 
Similarly, the conditions between a phase separated morphology and a partially 
encapsulated morphology can be determined when it is assumed that ΔAP1,P2 = -dA, ΔAP1,L = dA, 
and ΔAP2,L = dA (Figure 2.7C). The difference in energy between EPS (phase separated) and EPE 
can be written as Equation 2.7 which defines a stable phase separated condition. 






From this, the condition for a stable phase separated morphology can be simplified to 
Equation 2.8. 
Equation 2.8  𝛾𝑃1𝑃2 > 𝛾𝑃2𝐿 + 𝛾𝑃1𝐿  
 
The conditions for a partially encapsulated morphology can then be determined from 
Equation 2.9 and  Equation 2.10 to give the simplified conditions (Equation 2.11 and Equation 
2.12).  
Equation 2.9  𝐸𝐶𝑆 − 𝐸𝑃𝐸 = 𝛾𝑃1𝐿𝑑𝐴 + 𝛾𝑃1𝑃2𝑑𝐴 − 𝛾𝑃2𝐿𝑑𝐴 > 0  
 
Equation 2.10   𝐸𝑃𝑆 − 𝐸𝑃𝐸 = 𝛾𝑃1𝐿𝑑𝐴 − 𝛾𝑃1𝑃2𝑑𝐴 + 𝛾𝑃2𝐿𝑑𝐴 > 0  
 
Equation 2.11  𝛾𝑃1𝑃2 > 𝛾𝑃2𝐿 − 𝛾𝑃1𝐿  
 
Equation 2.12  𝛾𝑃1𝑃2 < 𝛾𝑃2𝐿 + 𝛾𝑃1𝐿  
 
Additionally, for partially encapsulated particles, the degree of encapsulation can be 
defined as the encapsulation ration (ER) (Equation 2.13) where h is the height of the particle of 
phase P2 encapsulated within phase P1, and D2 is the diameter of the P2 phase compartment (Figure 
2.7D).  
Equation 2.13  𝐸𝑅 = ℎ 𝐷2
⁄   
 
With this definition, h = D2 and ER = 1 for a core-shell particle and for any particle with 
h < D2, a portion of P2 will be exposed and the particle will have a partially encapsulated 
morphology. For a phase separated particle, h = 0 and ER = 0, and no portion of P2 will be 
encapsulated within P1.  
The encapsulated phase P2 does not have a perfect spherical shape, but it instead takes a 
lens shape of a finite angle, α, as seen in (Figure 2.6). This effect comes from the polymers and 





reduce the total interfacial energy of the system. It is possible to estimate α and θ (the angle 
between the P1-P2 interface and the P1-L interface) by balancing the interfacial surface tension 
vectors (Figure 2.7E) at the three phase contact line78. This results in Equation 2.14 and Equation 
2.15. Note that at the boundary conditions of α = 0° (completely phase separated) and α = 180° 
(core-shell) corresponds to the limiting conditions given by Equation 2.6, Equation 2.11 and 
Equation 2.12. 
















Finally, the total interfacial energy equation (Equation 2.3) can be written as a function of 
h and D2, which make up the encapsulation ratio (Equation 2.13), instead of A, thus creating a 
model which can predict the morphology of a given biphasic particle system upon reconfiguration. 
For this model, P2 was assumed to always be a sphere which would make D2 a constant equal to 
2r2. The shared interface between P1 and P2, (AP1,P2) will be the surface area of a spherical cap that 
will increase with an increase in h (Figure 2.7F, Equation 2.16).   
Equation 2.16  𝐴𝑃1𝑃2 = 𝜋(𝑎
2 + ℎ2)  
 
The radius of the spherical cap, a, can be written as a2 in terms of h using the equation of 
a circle (Figure 2.7G). Equation 2.17 and Equation 2.18, show the simplified definitions of a2 and 
AP1,P2, respectively.  
Equation 2.17  𝑎2 = ℎ𝐷2 − ℎ
2  
 






 The area of the interface between P2 and the liquid medium (L) is AP2,L and will be the 
surface area of P2 less the area in contact with P1 which was previously defined in Equation 2.18. 
This area will also be a function of h as AP2,L (Equation 2.19) will decrease with an increase in h.  
Equation 2.19  𝐴𝑃2𝐿 = 𝜋𝐷2
2 − 𝜋ℎ𝐷2  
 
 AP1,L is the area of the interface between P1 and the liquid medium (L) and will change 
based on the volume of P2 that is engulfed within P1. The volume of P2 that is engulfed, VP2cap, 
will be the volume of the spherical cap highlighted in Figure 2.7F, however the equation of a 
sphere (Figure 2.7H) will be used to define a2 and VP2cap in terms of h as shown in Equation 2.20 
and Equation 2.21, respectively. The combined volume of P1 and VP2cap is V1,2 (Equation 2.22) 
where D1 is the diameter of P1 if it was a spherical, single-phase particle.   


























𝜋ℎ3    
 
V1,2 will take the shape of a spherical cap with a as the radius of the cap and h1,2 as the 
height of the cap (Figure 2.7I) as defined by Equation 2.23 which will be equal to Equation 2.22. 
Setting Equation 2.22 equal to Equation 2.23 and solving for h1,2 in terms of h results in Equation 
2.24. h1,2 as a function of h can now be substituted into AP1,L to create a definition for the interface 
area between P1 and the liquid medium (Figure 2.7I) as a function of h (Equation 2.25). 






















   
 
Equation 2.24a  𝑚 = ℎ3 − 3ℎ2𝐷2 − 2𝐷1





Equation 2.24b  𝑛 = ℎ𝐷2 − ℎ
2  
Equation 2.25  𝐴𝑃1𝐿 = 𝜋(ℎ1,2
2 + ℎ𝐷2 − ℎ
2)   
 
 With all three interface terms, AP1,P2 (Equation 2.18), AP2,L (Equation 2.19) and AP1,L 
(Equation 2.25) defined in terms of h, the total interfacial energy, E (Equation 2.3), can be plotted 
against the encapsulation ratio (ER) and the minimum found. The ER at the minimum E will predict 
if the particle will be a core-shell (ER = 1), partially encapsulated (1 > ER > 0), or phase separated 






Figure 2.7: Schematics of a spherical biphasic particle used in determining the resulting spherical 
morphology 
A) Schematic of a biphasic, non-spherical particle and the three possible spherical morphologies 
that it can take upon reconfiguration. B) The boundary condition between a core-shell morphology 
and a partially encapsulated morphology is determined by this schematic. C) Schematic used to 
determine the boundary condition between a partially encapsulated morphology and that of a phase 
separated one. D) Schematic of the dimensions used to define the encapsulation ration (ER) of a 
partially encapsulated particle. E) Schematic of the lens angle between a partially encapsulated 
phase and the phase surrounding it based on the interfacial surface tension vectors. F) Schematic 
of the interfacial area AP1,P2 (red) between P1 (green) and P2 (blue). G) Plot of a circle used in 
describing the equation of a circle in terms of h and D2. H) Plot of a sphere used in describing the 
equation of a sphere in terms of h and D2. I) Schematic of the interfacial area AP1,L (red) and the 
defined dimensions.  
 
These predictive models were then applied to biphasic polymer systems to test their 
accuracy. The first biphasic system included poly(vinyl acetate) (PVAc) and polystyrene (PS), and 
the second system consisted of  poly(methyl methacrylate) (PMMA) and PS. A 50% water and 
50% gylcerol solution was utilized as the liquid medium during the shape reconfiguration at 
~140°C to accommodate the higher glass transition temperatures. The surface tensions (γlv) of 
water and glycerol at 140°C were calculated to be 53.4 mN/m and 52.5 mN/m, respectively, from 
experimentally determined surface tension values reported in the literature79,80. The surface tension 
of a 50% water-glycerol solution was estimated to be 52.9 mN/m, the average between the surface 
tensions of water and glycerol at 140°C. The ratio between the polar (γplv) and dispersive (γ
d
lv) 
components was assumed to be constant with temperature81, and that the polar and dispersive 
components of the 50% mixture was also the average of the pure water and glycerol values. Table 
2.1 lists surface tension values as well as the estimated polar and dispersive components of water, 
glycerol, and the projected values for a 50% water-glycerol solution. Literature values of polymer 
surface tensions (γsv) at 140°C of PS, PVAc and PMMA are listed in Table 2.2
82. 
Table 2.1: Liquid Surface tension values and estimated polar and dispersive components at 140°C  









Water 53.479 15.6 37.8 
Glycerol 52.580 33.6 18.9 
50% Water-50% Glycerol 52.9 24.6 28.3 
 
Table 2.2: Polymer surface tension values at 140°C reported by Wu82 





PS 32.1 26.7 5.4 
PVAc 28.6 19.2 9.4 
PMMA 32.0 23.0 9.0 
 
To estimate the interfacial surface tension between the 50% water-glycerol mixture and the 
polymer during the reconfiguration, the harmonic-mean equation was used (Equation 2.26)81. 
















Interfacial surface tensions between polymers were reported in the literature by Wu and 
were used in these calcualtions (Table 2.3)82.  Based on these values and the boundary conditions 
determined previously, the PVAc-PS biphasic particle was predicted to have a partially 
encapsulated morphology and the PMMA-PS particle would be core-shell which is seen in Figure 
2.8. 
Table 2.3: Interfacial surface tensions of two biphasic particles systems suspended in 50% water-
50% glycerol 
Particle System (P1/P2) γP1,L (mN/m) γP1,P2 (mN/m) γP2,L (mN/m) 
PVAc/PS 18.3 3.782 19.8 
PMMA/PS 15.7 1.782 19.8 
 
Calculating the lens angle in both systems gives θ = 72.8° and α = 117.5° for the PVAc-PS 





with the observed particles (Figure 2.8A, C). Additionally, plotting E against ER for both particle 
systems to find Emin results in ER = 0.66 and ER = 1 for the PVAc-PS and PMMA-PS systems, 
respectively, which also matches the observed morphology of the particles (Figure 2.8B, D). 
 
Figure 2.8: Two biphasic particle systems with different spherical morphologies 
A) Fluorescent microscopy of PVAc(red)-PS(blue) biphasic particles showing a partially 
encapsulated morphology. B) E vs ER plot for the PVAc-PS particles showing Emin ~ 0.66 with 
the inset showing a schematic of the morphology. C) Fluorescent microscopy of PMMA(green)-
PS(blue) biphasic particles with a core-shell morphology. D) E vs ER plot for the PMMA-PS 
particles showing Emin = 1 indicating a core-shell morphology with a schematic of the morphology 
in the inset.  
  
2.2.3 Reduction in Particle Size to Nanoscale 
The majority of particles fabricated using the WETS method shown up to this point are 
greater than 1 μm in diameter and are therefore too large to use for a systematic drug delivery 
study. In order to reduce the overall size of particles produced with WETS, the width of the 
wettable domains (W) would need to be reduced. Several options for reducing W were investigated, 
but first, limits of the current fabrication method were determined. As an ideal target for spherical 
particles, 100 nm and 200 nm diameter spheres were chosen. The non-spherical particle thickness 
(Equation 2.1) and the spherical particle diameter (Equation 2.2) equations were used to project 
what non-spherical particle thicknesses and widths would be required (Figure 2.9). Values from 
the plot are listed in Table 2.4 and show that for a 200 nm spherical particle, W ≤ 2 μm would be 






Figure 2.9: Determining required particle thicknesses and domain widths to fabricate 100 nm and 
200 nm spherical particles 
A) Schematic of a non-spherical particle showing t, the particle thickness, and W, the width of the 
domain and particle. Listed below are the equations that define the particle thickness based on dip-
coating solutions and parameters, and the spherical particle diameter post-reconfiguration. B) Plot 
showing how spherical diameter changes for 5 different values of W over a thickness of 0 to 10 
nm. Dashed lines indicate spherical diameters of 100 nm and 200 nm.  
 
Table 2.4: Required particle thickness for 100 nm and 200 nm spherical particles based on the non-
spherical particle width  
Spherical Diameter (nm) Non-spherical Width (μm) Non-spherical Thickness (nm) 
100 5.00 0 
100 3.00 0 
100 2.00 0 
100 1.00 1 
100 0.75 2 
200 5.00 0 
200 3.00 1 
200 2.00 3 
200 1.00 11 






The limit of resolution of standard lithography, the method used to fabricate the WETS 
surfaces, is 2 μm which could be used to fabricate spherical 200 nm particles. However, this would 
be the upper limit, and non-spherical particles would be limited to 2 μm as well. One method of 
reducing W would be to use a stepper in conjunction with standard lithography. The stepper can 
reduce the pattern of a patterned quartz mask 5 times and to repeat this reduced pattern across the 
surface of a 4-inch silicon wafer to pattern the entire area. WETS templates were fabricated at the 
stepper’s limit of resolution, 700 nm, and particles were fabricated and analyzed with AFM (Figure 
2.10A-D) and SEM (Figure 2.10E-H) showing uniform non-spherical particle assemblies which 
could be released and collected. Another method investigated used block copolymer lithography 
to fabricate W = 25 nm WETS templates which was able to produce 25 nm particle assemblies on 
the templates (Figure 2.10I-P). However, release and collection of the 25 nm particles was difficult 
and very few particles were able to be harvested making this method unsuitable for larger scale 
production. Another method investigated but not attempted was e-beam lithography as this method 
has a limit of resolution of less than 10 nm. Generally, e-beam lithography is used for custom, one-
time fabrication as the rate of etching is extremely slow, and as WETS would require a high rate 
of substrate fabrication this method was deemed non-viable. This left the stepper as the best option 






Figure 2.10: 700 nm and 25 nm WETS particles fabricated with stepper lithography and block 
copolymer lithography 
AFM scans of A) 700 nm wettable, TiO2 domains fabricated with a stepper. B) The release layer 
PSS deposited on the 700 nm wettable domains. C) PS deposited on top of PSS as the first polymer 
layer of the WETS particle. D) PEGDA deposited on top of PS and PSS. SEM images of each step 
of the 700 nm particles: E) 700 nm wettable, TiO2 domains, F) PSS dip-coated onto the wettable 
domains, G) PS dip-coated on top of PSS and H) PEGDA dip-coated on top of PS and PSS. SEM 
images of I) the 25 nm block copolymer fabricated WETS templates with wettable, TiO2 domains, 
J) PSS dip-coated onto the wettable domains, K) PS dip-coated onto PSS, L) PEGDA dip-coated 
onto PS and PSS. AFM scans of M) 25 nm wettable, TiO2 domains fabricated with block 
copolymer lithography, N) PSS dip-coated onto the 25 nm wettable domains, O) PS dip-coated 






2.2.4 Modification of WETS Substrate for Increased Particle Production  
Original production levels of WETS resulted in enough particles for characterization, but 
not enough for in vitro studies which were estimated to need ~1012 particles per experiment. In 
order to increase the number of particles produced with WETS, two different approaches were 
investigated and combined: 1) increase the reliability and reusability of the WETS substrates, and 
2) scale up fabrication of the particles by increasing the size of the WETS substrate. The first 
method would reduce time needed in fabricating the substrates and would additionally increase the 
number of usable, monodisperse particle samples. This would also allow for consolidation of 
different batches as batch-to-batch variability would be removed. The second method would make 
more particles per batch, thus reducing the time needed to make a sufficient number of particles.  
2.2.4.1 Modified Lithography Fabrication 
The original WETS substrate fabrication relied on a silicon substrate that was blanketed 
with TiO2 through physical vapor deposition, silanized with a non-wetting silane and then the 
silane was selectively cleaved from the TiO2 surface with ultraviolet (UV) radiation through a 
quartz photomask to form the discrete, wettable domains surrounded by a non-wetting background 
(Figure 2.11A). This substrate fabrication method was faster, however, the high energy state of 
TiO2 is not permeant, and re-activation through UV or oxygen plasma would remove the non-
wetting background. Over extended uses of the substrate, the size of the wettable domain would 
shrink, creating particles of smaller and smaller widths until particles no longer patterned on the 
surface (Figure 2.11B). Additionally, in flawed areas of the silanization, polymer from the dip-
coating solution would begin to film across the substrate in larger and larger areas, reducing the 






Figure 2.11: Simple WETS substrate fabrication method 
A) Original fabrication method of WETS substrates where a silicon wafer was blanketed in 5 nm 
of TiO2, silanized to create a non-wetting surface and then exposed to UV radiation through a 
quartz photomask to pattern discrete wettable domains in the non-wetting background. B) 
Repeated uses of the same WETS substrate, imaged with optical microscopy, showing the 
reduction in particle size as the wettable domains slowly revert to non-wetting over time. C) 
Optical microscopy images of the same WETS substrate imaged over time showing the increase 
in polymer filming on the surface due to flaws in the silanization of the non-wetting background.  
 
In order to address these short comings, a new photolithography method (Figure 2.12A) 
was used which would enable WETS substrates to be reusable. This method would use a 





domains, such that when the TiO2 was deposited it formed discrete domains instead of blanketing 
the entire silicon wafer (Figure 2.12B). After the photoresist was removed, the substrate was 
silanized rendering the entire face non-wettable. Then the substrate was exposed to UV radiation 
which selectively removes the silane from only the TiO2 domains and activates the domains to 
become wetting, while leaving the silanized silicon background unchanged. This substrate was 
now able to be reused as repeated UV exposure would re-activate the TiO2 and smaller flaws in 
the silanization of the silicon background can be ‘cleaned’ as the UV radiation breaks down tiny 






Figure 2.12: New photolithography method to fabricate WETS substrates with discrete TiO2 
domains 
A) WETS substrate fabrication method using standard photolithography steps to create discrete 
TiO2 domains using 1813 photoresist paired with LOR. The size and shape of the wettable domains 
were determined by the pattern on the quartz photomask which was used to pattern the photoresist. 
TiO2 was deposited on the developed photoresist, and after removal of the photoresist the substrate 
is silanized. UV radiation selectively removes the non-wetting silane from the TiO2 domains and 
makes the domains wettable. B) Cross-section schematic of the LOR/1813 combination used to 
enable the patterning of TiO2 domains. Number 1, 2 and 3 correspond to steps labeled in (A). C) 
AFM scan of an individual, 10 nm tall TiO2 domain.  
 
With this new method, the WETS substrates were able to be used consistently for multiple 
uses (Figure 2.13), and were able to be cleaned with solvent washes and UV radiation between 
batches of particles.  
 
Figure 2.13: Optical images of particles on the new WETS substrates 
A) A new WETS substrate with the release layer dip-coated. Successive B) second, C) third, D) 
fourth, E) fifth and F) sixth uses of the same WETS substrate with the release layer consistently 
the same size as the first use.  
 
2.2.4.2 Increased Substrate Size  
Production of WETS particles is based on the size of the WETS substrate and the density 





the center-to-center distance between wettable domains will increase the number of particles 
produced in each batch. Particles produced for characterization had originally been produced on 
substrates that were 1.0 – 2.5 cm2 and were dip-coated in small glass vials or jars (Figure 2.14A) 
and were small enough to be accommodated in-house. In order to scale up to using an entire 4-
inch silicon wafer, a larger dip-coating chamber had to be fabricated (Figure 2.14B) and several 
substrate processing steps were moved to a cleanroom as the equipment was able to accommodate 
the larger wafers. As a part of the scale-up testing, a 20 µm center-to-center photomask was 
purchased to uniformly pattern a 4-inch wafer. This increased the number of particles able to be 
produced due to the smaller center-to-center distance and the larger area of the photomask. Table 
2.5 lists current in-house photomask patterns and the number of particles which could be patterned 
on its area. Additionally, 3 theoretical photomasks are listed as these were the next designs planned. 
Based on published methodologies, the number of nanoparticles delivered for a single condition 
in an in vitro cell study ranged from 107 to 1027 nanoparticles83–86, and was ~1012 nanoparticles for 
my electrospray experiments in Chapter 3 and 4. Even with the theoretical, 1.5 µm center-to-center 
substrate (highest number of particles/substrate), the substrate would have to be dip-coated ~300 
times to produce enough particles. This demonstrated that a larger increase in production than the 
single 4-inch wafer would be needed. Future routes to accomplish this can be done by either 
reducing the center-to-center spacing further, increasing the size of the wafer to 6 or 12 inches, 
developing a multiple substrate dip-coating apparatus or designing a roll to roll dip-coating set up 






Figure 2.14: Small and large scale dip-coating set ups 
A) Small scale dip-coating set up with a syringe pump to withdraw the WETS substrate from the 
polymer solution at a steady rate. The small substrate could fit in the glass jar which was used as 
the solution reservoir. B) Large scale dip-coating set up with the same syringe pump to set the 
withdrawal rate. The dip-coating chamber is a custom designed glass chamber which is large 
enough to accommodate a 4-inch WETS substrate.  
 
Table 2.5: Photomask center-to-center spacing and particle yield 















50 2.58 x 105 – 
45 3.19 x 105 – 
40 – 5.07 x 107 
30 7.17 x 105 – 








10 – 8.11 x 107 
5 – 3.24 x108 






2.2.5 Nanoscale Fouling of Non-wettable Silane 
The highly fluorinated silane which was chosen to form the non-wettable background 
displayed high contact angles for both aqueous and organic solvents as well as polymer solutions 
(Table 2.6). In addition, small scale substrates (1.0 – 2.5 cm2) had been re-used up to 20 times with 
continued receding of the polymer solution from the non-wettable background during dip-coating.  
Table 2.6: Advancing (θAdv) and receding (θRec) contact angles for various liquids and polymer 
solutions on the non-wettable, fluorinated silane 
Liquid 
Contact Angle 
θAdv (°) θRec (°) 
Water 120 112 
Dimethylformamide (DMF) 76 66 
Toluene 72 62 
Ethanol 50 38 
Hexane 47 33 
Acetone 62 47 
Methanol 52 39 
Isopropanol 56 42 
Tetrahydrofuran (THF) 66 53 
Chloroform  64 51 
PSS – water  108 97 
PS – toluene  72 58 
PMMA – toluene  70 57 
PMMA – DMF  73 60 
PEGDA – DMF  78 68 
PMMA – chloroform 58 42 
 
However, it was found that when the substrate area was increased from 1.0 – 2.5 cm2 to a 
full size 4-inch silicon wafer that the polymer solution would not recede fully from the substrate 





nanoscale polymer fouling of the silane through an increase in roughness (Figure 2.15B-E). 
Additionally, when the substrate is submerged in a polymer solution for 5 minutes, there is a 
change in the contact angle, notably a large decrease when submerged in the PSS+H2O solution 
(Table 2.7). Decreases in contact angle prevent the solution from receding from the substrate as 
the solution is more likely to pin which would enable evaporation of the solvent and the polymer 
would be left behind to form a film. It is suggested that the polymer solutions were able to recede 
from the small-scale substrates despite the nanoscale fouling because they were on the same length 
scale as the capillary lengths (lc) of the polymer solutions, roughly 2lc. This would enable cohesion 
forces to assist in the receding of the solution from the edge of the substrate where with the 4-inch 
substrate, the width of the substrate was much larger than 2lc. This is supported by the polymer 
film forming ~lc inside the edge of the 4-inch wafer (Figure 2.15A) and receding between the edge 
of the wafer and ~lc. Furthermore, silicon wafers fabricated as 4-inch substrates that were broken 
down into 1.0 – 2.5 cm2 substrates and dip-coated, did not exhibit polymer filming as the solution 






Figure 2.15: Polymer fouling of WETS substrates 
A) Picture of a 4-inch WETS substrate where the polymer solution did not recede from the wettable 
background and formed a film on the substrate. AFM scans of B) the silanized, non-wettable 
background, C) PSS nanoscale fouling of the non-wettable background after dip-coating, D) 
PLGA nanoscale fouling of the non-wettable background after PSS and PLGA dip-coating, and 
E) residual polymer fouling in the non-wettable background after washing the substrate with 
solvents for PSS and PLGA.  
 
Table 2.7: Changes in contact angle after submerging in various polymer solutions for 5 minutes 
Polymer Solution 
Initial Contact Angle Change in Contact Angle 
θAdv (°) θRec (°) θAdv (°) θRec (°) 
PLGA + Ethyl Acetate 110 74 0 -9 
PLGA + Chloroform 110 71 +1 -11 
PLGA + Dichloromethane 113 85 +4 +2 







The WETS method was shown as a viable technique to make multiphasic spherical and 
non-spherical particles in a large range of sizes and shapes. This versatility is ideal for fabricating 
particles for a systematic study of how particle properties impact particle behavior in vivo. The 
key factor of the WETS method is the independent control of each property that enables direct 
comparison between size, shape, and chemistry. Polymer solutions and dip-coating parameters can 
be adjusted such that particles with exact specifications can be fabricated as predictive models 
have been developed for both spherical and non-spherical models. Additionally, temperature 
stimulated particles could also be employed. Nanoparticle fabrication has been demonstrated by 
using a stepper to reduce the size of the wettable domain on the WETS substrate, and protocols 
have been developed to accommodate a reusable 4-inch substrate for increased production. 
However, due to the discovery of nanoscale fouling which renders the 4-inch substrate unusable, 
investigations into alternate non-wetting silanes, such as 1,3-PDMS, need to be conducted to allow 
for scaling up of the WETS system. Scale-up of WETS particle production will need to continue 
past the expansion to a single 4-inch substrate as even with a theoretical center-to-center spacing 
of 1.5 μm, the substrate would have to be dip-coated hundreds of times. Future work will need to 
focus on continued scale up by employing larger substrates, multiple substrate dip-coating or 
another form of automation.  
2.4 Materials and Methods 
2.4.1 Materials 
Heptadecafluoro-1,1,2,2-tetrahydrodecyl)trichlorosilane (HDFTS) was purchased from 
Gelest Inc. Poly(vinylidene fluoride) (PVDF, Mw = 275kDa), polystyrene (PS, Mw = 1.2kDA, 





poly(vinyl acetate) (PVAc, ≈ 25 kDa), poly(methyl methacrylate) (PMMA, ≈ 25 kDa), 
poly(ethyleneglycol)diacrylate (PEGDA, Mw = 700Da), poly(4-vinylphenol) (PVP, Mw = 25 kDa), 
Poly(D,L-lactide-co-glycolide) (PLGA, 24-38 kDa, lactide:glycolide 50:50, acid terminated), 
poly(allylaminehydrochloride) (PAH, Mw = 15 kDa). Rhodamine B, fluorescein isothiocyanate 
isomer I (FITC), 4’, poly[tris(2,5-bis(hexyloxy)-1,4-phenylenevinylene)-alt-(1,3-
phenylenevinylene)] (PTDPV, blue), 6-diamidino-2-phenylindole dihydrochloride (DAPI). 
Dimethylformamide (DMF), toluene, ethylene glycol, heptane, ethanol, chloroform propylene 
glycol monomethyl ether acetate (PGMEA) and perfluorodecalin (PFD) were purchased from 
Sigma-Aldrich. Ferrofluid (EMG 304) was purchased from Ferrotec. Silicon wafers were obtained 
from the Lurie Nanofabrication Facility at the University of Michigan. 
2.4.2 WETS Substrate Fabrication  
2.4.2.1 Blanket TiO2 Method 
A ~5 nm thin film of titanium dioxide (TiO2) was deposited on to a 4-inch silicon wafer 
through physical vapor deposition. The TiO2 coated silicon was then plasma treated for 15 minutes 
and then silanized with HDFTS through chemical vapor deposition at 100°C for 30 minutes 
rendering the surface non-wettable. To create patterned wettable domains, the silanized TiO2 
surfaces were radiated with ultraviolet light (UV, 254 nm) for 90-120 minutes through quartz 
photomasks which were patterned with the wettable domain size and shape. The resulting template 
had a non-wetting background and patterned wettable domains with controlled geometry and 
spacing.  
2.4.2.2 Discrete TiO2 Lithography Method  
The 4-inch silicon wafer was cleaned with a plasma strip for 6 minutes and then coated 






photoresist was then UV exposed through a quartz mask patterned with the wettable domain size 
and shape. Following UV exposure, the photoresist was developed so that the 1813 slightly over 
hangs the LOR underneath of it. The wafer was then gently cleaned with a plasma descum step for 
20 seconds before 10 nm of TiO2 was deposited with physical vapor deposition. The photoresist 
was then lifted off and the entire wafer cleaned again with a 6-minute plasma strip. The now 
activated substrate was silanized with HDFTS at 120°C for 2 hours rendering the entire substrate 
non-wettable. The HDFTS was then cleaved from the TiO2, wettable domains by UV radiation for 
45 minutes reversing the domains to be completely wettable.  
2.4.2.3 Stepper Lithography Method 
A plasma cleaned 4-inch silicon wafer was coated in 3 μm of SPR 220 photoresist and 
baked. The photoresist was then patterned with UV radiation through a quartz masking using a 
stepper (GCA AS200 Autostep) to create an array of 700 nm discrete domains following 
development. 15 nm of TiO2 was then deposited with physical vapor deposition and the photoresist 
was lifted off. The substrate was then silanized with HDFTS and UV exposed the same as the TiO2 
discrete method listed previously to form a patterned wettability substrate.  
2.4.2.4 Block Copolymer Lithography Method 
Block copolymer lithography was carried out using an asymmetric block copolymer, 
polystyrene-block poly(methyl methacrylate) (PS-b-PMMA, MWPS = 46 kDa, MWPMMA= 21 
kDA). After thermal annealing and the selective plasma etching of PMMA, PS-b-PMMA formed 
cylindrical nanostructures with 25 nm diameters in a hexagonally packed array on a 4-inch silicon 
wafer. 5 nm of TiO2 was then deposited with physical vapor deposition and the block copolymer 
removed with a solvent wash. The substrate was then silanized with HDFTS and UV exposed the 





2.4.3 Particle Fabrication Method  
2.4.3.1 Dip-coating  
15 wt% polymer solutions included PSS-water, PVDF-DMF, and PS-toluene. 25 wt% 
PVP-ethanol, 2.5 wt% PAH-water, 2.5 wt% PSS-water and 10-55 wt% PLGA-chloroform were 
also used. All solutions were dip-coated using a KD Scientific syringe pump at a constant dip-
coating velocity of 0.1 to 1 cm/s.  
2.4.3.2 Particle Harvesting  
Particles were collected from the WETS substrate by holding the substrate vertically over 
a collection vial and gently washing with the release layer solvent (generally water). With the 
dissolution of the particles, the solvent droplet would recede down and off the substrate taking the 
released particles with it. Harvesting efficiency can be check with optical microscopy. 
2.4.3.3 Particle Reconfiguration 
Shape reconfiguration of non-spherical particles was carried out by heating a particle-water 
dispersion above the glass transition temperatures (Tg) of all polymers comprising the particle. In 
case of particles that have a Tg higher than 100°C a 1:1 glycerol-water mixture was used. Spherical 
particles can then be collected after particle sedimentation with centrifugation or through water 
evaporation. 
2.4.4 Characterization Methods 
2.4.4.1 Contact Angle Measurements 
Contact angle was measured using a Ram-Hart 200-F1 goniometer. Advancing contact 
angle was measured by expelling 2-10 μL of liquid onto a surface and the receding contact angle 
was measured by removing 2-10 μL of liquid from a surface with a 2 mL micrometer syringe 





2.4.4.2 Optical Microscopy 
Optical microscopy was conducted with a VistaVision VWR optical microscope.  
2.4.4.3 Atomic Force Microscopy (AFM) 
Tapping mode AFM was conducted using a Veeco Innova with Veeco TESPA tips and Hi 
Res C probes.  
2.4.4.4 Fluorescent Microscopy 
Fluorescent microscopy was carried out with an Olympus BX 51 microscope. Confocal 
laser scanning microscopy was conducted with a Nikon A1 Confocal with lasers: 405 nm, 488 nm, 
and 533 nm.  
2.4.4.5 Scanning Electron Microscopy (SEM) 








Chapter 3: Co-Delivery Nanoparticles to Target Ovarian Cancer Stem Cells and 
Platelet-Derived Growth Factor Mediated Signaling from Mesenchymal Stem Cells 
3.1 Introduction 
3.1.1 Cancer Stem Cells Show Increased Chemoresistance, Metastasis and ALDH 
Expression Due to PDGF Signaling with Mesenchymal Stem Cells  
Ovarian cancer stem cells (CSC) have been linked to increased chemoresistance, metastasis 
and proliferation, and are thought to be the main driver in patient relapse following clinical 
treatment6–8,20,87,88. CSC have been identified to have increased aldehyde dehydrogenases (ALDH) 
activity and high CD133 expression, and detection of these cells is a predictor of poor patient 
outcomes89–94. In the ovarian cancer microenvironment, CSC interact dynamically with other cells, 
some of which become CSC-supportive including mesenchymal stem cells (MSC)9,95. MSC 
reprogramming arises from bi-directional signaling between CSC and MSC through IL-6, SDF-1, 
TGF-β, BMP2, BMP4, CCL5 and platelet-derived growth factor (PDGF)3,9,15,18,95,96. Previously, 
PDGF signaling between CSC and MSC has been shown to increase CSC platinum resistance, 
migration, epithelial to mesenchymal (EMT) markers and ALDH expression3. Additionally, 
sunitinib, a tyrosine kinase inhibitor which interrupts CSC-MSC communication through PDGF, 
was shown to negate the increase in platinum resistance, and was suggested as a potential therapy 





3.1.2 Nanoparticles for Co-delivery of Sunitinib and Paclitaxel 
Encapsulation of chemotherapeutics in a polymer nanoparticle increases the solubility, 
circulation and targeting of the delivered drugs. Paclitaxel, an antimicrotuble ovarian cancer 
therapy, has previously been encapsulated in a nanoparticle and showed increased solubility and 
cytoxicity84,97–99. Sunitinib has also been delivered as a nanoformulation for cancer therapy and 
found to be effective, but it has not been studied as extensively as paclitaxel100–102. Sunitinib and 
paclitaxel have been delivered together in a 3 patient case study, where paclitaxel was delivered 
in the form of an albumin nanoparticle and sunitinib was delivered as a free drug. Improvements 
in all 3 lung cancer patients were observed in the form of reduced tumor mass and a lessening in 
symptoms with co-delivery103. Co-delivery where both drugs were encapsulated in the 
nanoparticle have generally been found to be more effective, and the first co-delivery formulation 
was approved by the FDA in 201729. In this work, a polymer nanoparticle which encapsulates both 
paclitaxel and sunitinib will be fabricated and characterized. In addition, the effectiveness of 
treating a co-culture of ovarian CSC and MSC with paclitaxel and sunitinib will be studied. 
3.2 Results and Discussion 
3.2.1 Nanoparticle Fabrication and Characterization 
3.2.1.1 Electrospray Parameter Determination  
Polymer nanoparticles made of poly (D,L-lactide-co-glycolide) (PLGA) were fabricated 
using an electrospray system (Figure 3.1) where a syringe pump was placed on top of an aluminum 
frame such that the syringe would point down towards the collection plate. A voltage was applied 






Figure 3.1: Nanoparticle Electrospray set up 
 
Identification of the spray solution was carried out through a systematic study of first the 
solvents and then the spray conditions in order to determine a formulation, and corresponding 
parameters, that results in a spherical nanoparticle with an average diameter of 200 nm or less. 
Various solvent combinations were identified from the literature and tested with 2 vol% PLGA 
and a flow rate of 0.1 mL/hr. Particles were sprayed onto aluminum pans and imaged with scanning 
electron microscopy (SEM) to evaluate size and morphology (Figure 3.2). Solvents used include 
dimethylformamide (DMF), acetonitrile (ACN), chloroform, dimethyl sulfoxide (DMSO), 
triethylammonium formate (TEAF), 2,2,2-trifluoroethanol (TFE) and sodium chloride (NaCl). 
Table 3.1 lists the associated solvents and nanoparticle diameters and standard deviations from 
Figure 3.2. From this test, a solvent combination of 25% ACN, 75% DMF and 10 μL TEAF (Figure 
3.2B), which results in uniform, 143 ± 27 nm nanoparticles, was chosen as the best formulation 






Figure 3.2: SEM images of PLGA nanoparticles with various solvent ratios 
A) 5% TEAF and 95% DMF, B) 25% ACN, 75% DMF and 10 μL TEAF, C) 25% TFE and 75% 
DMF, D) 50% ACN and 50% DMF, E) 25% chloroform and 75% DMF, F) 25% ACN, 75% 
DMSO and 10 μL TEAF, G) 50% chloroform and 50% DMF, H) 1% NaCl and 99% DMSO  
 
Table 3.1: Solution parameters of PLGA nanoparticles and their diameters 
Figure 3.2 Panel Solvent (vol%) Voltage (kV) Diameter (nm) 
A 5% TEAF and 95% DMF 7.5 124 ± 20 
B 25% ACN, 75% DMF and 10 μL TEAF 8.0 143 ± 27 
C 25% TFE and 75% DMF 8.0 195 ± 30 
D 50% ACN and 50% DMF 10.0 198 ± 55 
E 25% chloroform and 75% DMF 4.5 225 ± 44 
F 25% ACN, 75% DMSO, 10 μL TEAF 8.5 250 ± 66 
G 50% chloroform and 50% DMF 6.0 269 ± 94 
H 1% NaCl and 99% DMSO 6.0 –  
 
The next systematic study included adjustments in the electrospray set up: the addition of 





which was hypothesized to reduce the overall nanoparticle size. The air flow consisted of 
compressed air which entered the spray chamber next to the syringe and flowed down towards the 
collection plate. Adjustments in the electrospray solution included a reduction in ACN, TEAF and 
PLGA. Figure 3.3 shows SEM images of the nanoparticles sprayed with the various conditions 
and the measured nanoparticle diameters and standard deviations. The reduction in ACN by 50 μL 
from 255 μL to 205 μL did not seem to have an impact on the size of the nanoparticles, 171 ± 54 
nm vs 169 ± 48 nm. However, more nanoparticles that had not fully dried were seen in the form 
of dark, flat disks on the collection pan indicating that 255 μL ACN is needed to increase the rate 
of evaporation of the solvent. With the reduction in TEAF from 10 μL to 5 μL or 0 μL, the size of 
the nanoparticles increases to 259 ± 92 nm and 319 ± 398 nm, respectively. Reducing the PLGA 
vol% from 2 vol% to 1.5 vol% did not seem to have a large impact of the size or morphology of 
the particles (162 ± 54 nm). When comparing nanoparticles fabricated with the addition of an air 
flow to those from the standard electrospray set up, there is an increase in the presence of non-
spherical particles suggesting that the air flow distorts the spray droplets as they fly towards the 
collection plate. Reducing the flow rate to 50 μL/hr, which is half that of the standard set up, does 
not greatly impact particle size (170 ± 40 nm), however, it does double the amount of time needed 
to fabricate the same number of nanoparticles. From this the standard electrospray solution (25% 
ACN, 75% DMF and 10 μL TEAF) and set up (no air flow, 0.1 mL/hr solution flow rate) (Figure 
3.3A) were identified as the best parameters and used for further experiments due to the production 






Figure 3.3: SEM images of alterations to the electrospray solution and set up 
A) Standard electrospray solution (25% ACN, 75% DMF and 10 μL TEAF) with the standard 
electrospray set up (no air flow, solution flow rate of 100 μL/hr, B) a reduction of 50 μL of ACN 
to 205 μL with the standard electrospray set up, C) a 50% reduction of TEAF to 5 μL and the 
standard electrospray set up, D) no TEAF and the standard electrospray set up, E) 1.5 vol% PLGA 
instead of 2 vol% and the standard electrospray set up, F) the standard electrospray solution with 
added air flow during spraying, G) reduced ACN and added air flow, H) reduced TEAF and added 
air flow, I) no TEAF and added air flow, J) reduced vol% PLGA and added air flow, K) the 
standard electrospray solution sprayed at 50 μL/hr instead of 100 μL/hr, L) reduced ACN and 
reduced flow rate during spraying, M) reduced TEAF and reduced flow rate, N) no TEAF and 
reduced flow rate, O) reduced vol% PLGA and reduced flow rate. Scale bar is 1 μm. 
 
3.2.1.2 Nanoparticle Collection  
Nanoparticle collection was carried out in either a ‘water bath’ (stirring 0.01% Tween 20 
and water solution) or onto an aluminum pan for a ‘dry’ collection. After a dry collection, the 
nanoparticles were harvested by scraping the particles off the surface of the pan with a plastic razor 
blade. Scraping was done within a puddle of ~5 mL 0.01% Tween 20 which would collect the 
particles removed from the pan. The puddle could then be scraped around the surface of the pan 
and pipetted off into a centrifuge tube to consolidate repeated scrapings of the same pan. For a 





poured off into a centrifuge tube. From this point, both the water bath and dry collection process 
were the same. The particle suspension in the centrifuge tube was probe sonicated to break up 
aggregates and then the suspension was poured through a 40 μm filter into a new centrifuge tube. 
The suspension was centrifuged for 15 minutes at 10,000 x g to pellet particles that are larger than 
1 μm and the supernatant was kept and centrifuged again for 60 minutes at 10,000 x g to pellet the 
nanoparticles. The supernatant was removed, and the nanoparticle pellet was resuspended in either 
water or cell medium. If there were multiple tubes for one sample, the particles were resuspended, 
combined, pelleted, and then resuspended a final time.  
Evaluation of the collection methods showed that for dry collection, scraping the pans was 
effective in removing all the nanoparticles from the surface (Figure 3.4A, B). However, this 
method was very labor and time intensive, and the water bath collection method removed the 
intermediate step of scraping all the collection pans multiple times. Particles collected with the 
water bath were centrifuge sorted and then drop casted onto a silicon chip for SEM imaging as 
they could not be imaged on the pan. The drop-casted particles (Figure 3.4C) were a mix of 
particles and short fibers. Investigation of the fiber’s origin proved that they were not electrospun 
as the morphology of electrospun fibers was very different (Figure 3.4D) and only rarely seen in 
an extreme condition of high drug loading when dry collected. Dry collection of particles showed 
that some of the larger droplets would not be fully dry when they impact the collection pan, and 
by extension the water bath. In the case of the dry pan, a wet polymer solution droplet would dry 
as a polymer film on the collection pan (Figure 3.4E).  However, in the case of the stirring water 
bath, the solvents (DMF and ACN) were water soluble and would diffuse out into the water bath 
leaving behind the polymer which was not water soluble. This diffusion was not instantaneous, 





elongate the polymer solution droplet. This elongated solution droplet then resulted in a fiber 
shaped polymer particle upon complete evaporation of the solvents, in addition to the spherical 
nanoparticles which were formed from completely evaporated polymer solution droplets (Figure 
3.4F). From this, the dry collection method was used to collect nanoparticles to ensure spherical 
nanoparticles.  
 
Figure 3.4: SEM images of nanoparticles from the dry and water bath collection methods 
A) Nanoparticles on an aluminum pan before collection. B) Image of an aluminum pan after 
scraping to collect the nanoparticles. C) Drop casted particles that were collected in a water bath. 
D) Electrospun beaded nanofiber fabricated with a high loading of paclitaxel in an extreme 
condition. E) Nanoparticles collected dry on an aluminum pan with two polymer films which were 
made from larger wet droplets that dried on the pan. The red arrow indicates that the films from 
dry collection may result in F) a fiber-like particle when they impact the stirring water bath instead 






3.2.1.3 Drug Loaded Nanoparticle Characterization 
Drug loaded nanoparticles were fabricated by adding powder drug to the electrospray 
solution and balancing the volume percent by reducing the amount of PLGA in the solution. Drug 
solutions were then sprayed with the same standard procedure as drug-free solutions and were dry 
collected to avoid the large fiber-like particles. Figure 3.5A-D show SEM images of control 
nanoparticles and drug loaded nanoparticles with diameters 100-150 nm. The particles were then 
collected from the aluminum pans, resuspended in 0.01% Tween 20 in water, centrifuge sorted 
and then quantified with nanoparticle tracking analysis (NTA). Hydrodynamic diameter was 
quantified by NTA and the histogram was plotted with the average indicated with a vertical dashed 
line (Figure 3.5E-H). Even with drug loading, the nanoparticles were less than 200 nm, and 
variation between the type of nanoparticles was within the range of error. The concentration of the 
nanoparticle suspensions was also measured with NTA and with the known volume of the 
suspension, the total number of nanoparticles fabricated with 3 batches was calculated (Table 3.2). 
Drug loading was done by pelleting a known number of nanoparticles, extracting the drug with 
ACN and then measuring the amount of drug with liquid chromatography-mass spectrometry 
(LCMS) as compared to known calibration curves (Figure 3.6). Table 3.2 lists all the data for the 
nanoparticles and the number of particles fabricated from the compilation of 3 batches and the 
associated drug loading. Based on the number of particles produced and their drug loading, it is 
estimated that it would take 746 hours (~4.4 weeks) of non-stop electrospraying to accumulate 
enough nanoparticles to conduct one cell study replicate. Due to this, nanoparticle cell studies were 
not conducted at this time as a major scale up in production (construction of ~7 more electrospray 
stations) would be required. Additionally, drug loading could possibly be improved by increasing 





could eventually lead to fiber formation in paclitaxel loaded particles as seen in Figure 3.4D, and 
the addition of more drug would be very expensive.  
 
Figure 3.5: Size characterization of control and drug loaded nanoparticles with SEM and NTA 
SEM images and measurements of A) control nanoparticles, B) paclitaxel loaded nanoparticles, 
C) sunitinib loaded nanoparticles and D) co-delivery paclitaxel and sunitinib nanoparticles. NTA 









Figure 3.6: LCMS calibration curves of known standards 
Calibration curves of known standards for A) paclitaxel and B) sunitinib.  
 










Control 149 ± 29 133 ± 52 2.0 x 1010 – 
Paclitaxel 135 ± 24 131 ± 43 2.3 x 1010 3.4 x 10-10 
Sunitinib 139 ± 32 133 ± 48 7.3 x 1010 5.6 x 10-11 
Paclitaxel + 
Sunitinib  
109 ± 36 145 ± 45 5.0 x 1010 
 1.0 x 10-9 + 
2.92 x 10-11 
 
3.2.2 Free Drug Co-culture  
Ovarian cancer stem cells (CSC) were represented by a high grade serous ovarian cancer 
cell line, OVCAR3, which had been sorted for ALDH and CD133 expression and were transducted 
to express green fluorescent protein (GFP+). Mesenchymal stem cells (MSC) were human adipose-
derived mesenchymal stem cells. Cells were cultured in 400 cell spheroids composed of, 300 MSC 





simultaneously as controls. Spheroids were incubated for 5 days to allow the cells to come together 
with 2 μL of fresh culture medium added on day 2 or 3. On day 5, spheroids were treated with 10 
μM paclitaxel, 5 μM sunitinib or a combination 10 μM paclitaxel + 5 μM sunitinib. On day 7, the 
spheroids were analyzed to understand the impact of co-culture and co-delivery on CSC stemness, 
chemoresistance and migration capacity.    
3.2.2.1 qPCR Analysis of CSC and MSC communication  
In the CSC-MSC co-cultures, MSC have been shown to produce PDGF which then binds 
to the CSC PDGF receptors starting a signaling cascade that can lead to increased chemoresistance, 
metastatic potential and increased ALDH expression3. In order to ensure that this communication 
is occurring in the 3D CSC-MSC co-culture, qPCR was conducted on CSC for PDGF receptor B 
(PDGFRB) and Indian Hedgehog (IHH) which have been shown previously to be involved3. MSC 
were removed from the analyzed cells by sorting for GFP+ CSC after the cells were harvested 
from the plates on day 7 using flow cytometry. As expected, there was an increase in the expression 
of PDGFRB and IHH in CSC when co-cultured with MSC (Figure 3.7), however this increase was 
not significant, less than a 2-fold change from CSC alone. Treating with sunitinib reduced the 
expression of PDGFRB and IHH in CSC more in the co-culture than in the CSC single culture, 






Figure 3.7: Quantification of CSC-MSC signaling with qPCR  
qPCR quantified fold change in CSC expression of A) PDGFRB and B) IHH. The red dotted line 
indicates the normalized value of the control. Grey bars were normalized to the CSC control 
condition while the black bars were normalized to the CSC-MSC control condition. 
 
3.2.2.2 Co-culture Live/Dead  
Cytotoxicity was evaluated using DAPI exclusion in flow cytometry for CSC single 
cultures and CSC-MSC co-cultures. MSC do not grow well alone in non-adherent 3D culture, 
therefore the MSC single culture was tested in a 96 well plate using a plate reader. MSC did not 
show significant death regardless of treatment, but the sunitinib condition was more alive than the 
control condition (Figure 3.8A). In the 3D cultures, there were no significant differences in 
viability, but conditions which were treated with a combination of paclitaxel and sunitinib showed 
the most death (CSC: 84% ± 8%, CSC-MSC: 88% ± 3%), while paclitaxel alone cased the next 
amount of death (CSC: 93% ± 5%, CSC-MSC: 91% ± 5%) (Figure 3.8B). Previous studies have 





however this data indicates that the same trend may not be true with a taxol based treatment. The 
data does match the observed phase contrast images (Figure 3.9). Visually the CSC-MSC 
spheroids were smaller than the CSC single cultures. It was expected that the combination 
treatment would cause more death due to the inhibition of crosstalk between CSC and MSC3, but 
as there was no significant up-regulation in PDGFRB or IHH gene expressions (Figure 3.7), non-
significant changes in viability are understandable.  
 
Figure 3.8: Live/Dead plots for MSC, CSC and CSC-MSC 
A) Plot of 2D MSC viability quantified from DAPI signal measured on a plate reader. B) Plot of 







Figure 3.9: Optical microscopy images of 3D CSC and CSC-MSC spheroids 
Day 3 images of A) CSC and B) CSC-MSC spheroids. Day 5 images of C) CSC and D) CSC-MSC 
spheroids. Day 7 images of control E) CSC and F) CSC-MSC spheroids, 10 μM paclitaxel treated 
G) CSC and H) CSC-MSC spheroids, 5 μM sunitinib treated I) CSC and J) CSC-MSC spheroids 
and combination 10 μM paclitaxel + 5 μM sunitinib treated K) CSC and L) CSC-MSC spheroids. 
Scale bar in all images is 400 μm.  
 
3.2.2.3 Changes in Stemness in CSC due to MSC Co-culture  
To evaluate CSC ALDH and CD133 expression, both markers of a stem cell phenotype in 
ovarian cancer cells89–94, spheroids were harvested on day 7 and then analyzed with flow cytometry 
and qPCR. For both methods, cells were sorted for GFP+ CSC prior to analysis to remove potential 
contamination with MSC ALDH or CD133 expression. It was expected that co-culturing CSC with 
MSC would increase the stem cell-like phenotype in CSC3, however a non-significant decrease in 





seen with qPCR (Figure 3.10B). In the qPCR plot, the dotted line represents the control condition 
(CSC or CSC-MSC based on the color) and a significant change would be 2-fold or higher. No 
change in ALDH activity or CD133 expression was seen with sunitinib treatment in the CSC only 
condition, but a non-significant decrease in stemness was seen in both flow cytometry and qPCR 
when the co-culture was treated with sunitinib. While not significant, a reduction in stem cell 
phenotype markers due to sunitinib treatment indicates that the PDGF signaling pathway between 
CSC and MSC is being disrupted. 
 
Figure 3.10: Changes in CSC ALDH activity and CD133 expression due to MSC co-culture and 
sunitinib treatment 
A) ALDH activity measured by flow cytometry. B) qPCR quantification of CD133 gene 
expression in CSC. The dotted line represents the control condition which is indicated by the color 
of the bar.  
 
1.2.5 Migration Potential and Epithelial to Mesenchymal Transition of CSC 
Migration potential of CSC was evaluated with a scratch assay after 7 days of 3D culture. 





the cells allowed to adhere to the plate. Once the cells were adhered, the monolayer was scratched 
and imaged at 0 hours and 24 hours to measure the reduced area (reported as a percent) of the 
scratch which indicates migration potential. MSC cells were not removed from the co-culture and 
only GFP+ CSC were quantified in the migration images (Figure 3.11A-H). No significant 
difference was seen between the tested conditions, but there was more migration in the control 
conditions than the 5 μM sunitinib treated conditions for both CSC and CSC-MSC (Figure 3.11I). 
This result was expected in the CSC-MSC condition as sunitinib is expected to inhibit PDGF 
signaling between CSC and MSC, which was previously linked to increased migration and 
epithelial-to-mesenchymal transition (EMT)3. However, it was expected that the CSC-MSC 
control would have a smaller area percent at 24 hours than the CSC control condition due to MSC 
mediated increase in migration potential which was not observed. Additionally, EMT potential 
was quantified by measuring the expression of N-cadherin in CSC using qPCR (Figure 3.11J). 
Fold change in expression was reported with the dotted line representing the control condition and 
the control condition denoted by the color of the bar. There was no significant difference in the 
expression of N-cadherin across the conditions, but there was a small increase in the CSC-MSC 
control compared to the CSC only control. This increase in N-cadherin is indicative of an increase 
in EMT in ovarian CSC and was expected to occur to do MSC co-culture3,104. Treatment with 
sunitinib also decreases the expression of N-cadherin in the CSC-MSC condition, aligning with 
the expected decrease in EMT when PDGF signaling is blocked. These non-significant changes in 
migration and N-cadherin expression could be due to the low expression of PDGFRB seen in CSC 







Figure 3.11: Migration and EMT potential of CSC due to MSC co-culture and sunitinib  
Scratch analysis images of GFP+ CSC. Control CSC at A) 0 hours and B) 24 hours, 5 μM sunitinib 
treated CSC at C) 0 hours and D) 24 hours, control CSC-MSC at E) 0 hours and F) 24 hours, and 
5 μM sunitinib treated CSC-MSC at G) 0 hours and H) 24 hours. Scale bar is 400 μm in all images. 
I) Plot quantifying the area percent of the scratch after 24 hours. J) Plot of N-cadherin gene 
expression in CSC quantified with qPCR. Dotted line represents the control condition with the 







Previous research had identified PDGF signaling between CSC and MSC as a method by 
which MSC would support CSC and, increase their chemoresistance, ALDH expression and 
migration potential3. Also identified was sunitinib, a tyrosine kinase inhibitor, which had been 
shown to negate the developed chemoresistance in CSC when delivered with a platinum based 
chemotherapeutic. In order to create a better delivery system for a chemotherapeutic and sunitinib, 
a co-delivery nanoparticle was developed using electrospraying. The nanoparticles were between 
150 nm and 200 nm and could encapsulate sunitinib, paclitaxel and both drugs together. However, 
the low nanoparticle yield from electrospraying prevented the testing of the co-delivery 
formulation at this time. Future work for this part of the project will be focused on increasing the 
scale of production. This could be accomplished through the construction of ~7 more identical 
electrospray stations, a multiplex electrospray set up105, development of a conveyor belt collection 
method which would increase the automation of the electrospray or a combination of these 
methods.  
Without the nanoparticle formulation, only co-delivery of the free drugs was tested in a 3D 
hanging drop platform. Single culture CSC were compared to CSC-MSC for PDGFRB and IHH 
expression with qPCR and it was found that there was a slight (not significant) increase in 
expression indicating some communication between CSC and MSC but not the large increase seen 
previously3. This lower amount of communication between CSC and MSC through PDGF is the 
probable cause for the equally small increases observed in ALDH activity, CD133 expression, 
migration potential and N-cadherin expression. Future work on this section of the project will be 
focused on improving the experimental design and understanding the difference between these 





3.4 Materials and Methods 
3.4.1 Cell culture and Materials 
Epithelial ovarian cancer cells, OVCAR3 (American Type Culture Collection), were 
transduced to express green fluorescent protein (GFP+) and were sorted to isolate the 
subpopulation which expressed CD133 and had high ALDH expression to represent the cancer 
stem cells (CSC). Human adipose-derived mesenchymal stem cells (MSC) were purchased from 
Lonza (PT-5006) were used without modification. All cells were used within 10 passages to avoid 
differentiation. MSC were cultured in 2D prior to plating in 3D in Lonza ADSC basal cell medium 
(PT-3273) supplemented with 10% fetal bovine serum, 5% Gibco antibiotic-antimycotic (100x), 
and 2mM of Gibco’s 200 mM L-glutamine. CSC were cultured in 2D prior to plating in 3D in 
Gibco RMPI 1640 cell medium with L-glutamine and phenol red and supplemented with 10% fetal 
bovine serum and 5% Gibco antibiotic-antimycotic (100x).  
To plate in a 384 hanging drop well plate for 3D culture, MSC were removed from 2D 
culture with Gibco 0.05% Trypsin–EDTA (1x) and the CSC were removed with Gibco 0.25% 
Trypsin–EDTA (1x). After counting, the cells were resuspended in the proper dilutions in a 50% 
MSC medium – 50% CSC medium mixture and plated in 20 μL droplets with 400 cells per droplet. 
The co-culture consisted of 300 MSC and 100 CSC while the single culture consisted of 400 CSC. 
Spheroids were cultured for 5 days with imaging and feeding (2 μL) on day 2 or 3. On day 5, the 
spheroids were imaged again, and drug treated. Drug incubation lasted for 2 days, and on day 7 






3.4.2 Flow Cytometry for ALDH Expression and Live/Dead 
On day 7, 154 spheroids from each condition were collected, resuspended in FACS buffer, 
and stained with AldeRed according to the AldeRed ALDH Detection Assay (SCR150, Sigma 
Aldrich) kit protocol. ALDH expression was analyzed for only GFP+ CSC in order to avoid 
potential expression from MSC. DAPI exclusion of live cells was used to quantify viability for 
live/dead analysis by resuspending cells in 1X PBS + 2% FBS + 300 μM 4’,6-diamidino-2-
phenylindole (DAPI) prior to FACS analysis.   
3.4.3 qPCR Assays 
308 wells for each condition were collected and resuspended in FACS buffer on day 7 in 
order to sort for GFP+ CSC using flow cytometry. The cell population with the highest GPF 
expression was selected as GPF+ CSC. After sorting, the cells were frozen until qPCR was 
performed. RNA was extracted using the RNeasy extraction kit (74104 Qiagen) and evaluated with 
a Nanodrop 2000 spectrophotometer (ND-2000 Thermo Fisher Scientific) before following a 
High-Capacity Reverse Transcriptase cDNA Transcription Kit (4368814 Life Technologies) to 
transcribe RNA to cDNA. RT-qPCR was performed on a 7900HT system through the University 
of Michigan Advanced Genomics Core. Data were analyzed using the 2-ΔΔCT method106. 
3.4.4 Migration Assay 
After 5 days of 3D culture and 2 days of treatment, 154 spheroids from each condition were 
collected and broken up, and the cells counted. Cells were then plated in a 96 well plate at 100,000 
cells/well in 200 µL of fresh cell medium and allowed to settle overnight. Once settled, a 200 µL 
pipette tip was used to scrape a horizontal wound in each well. The wound was then imaged using 





24 hours. The area of the wound was measured in ImageJ and the fraction of the original area still 
clear at 24 hours was calculated as a percent.  
3.4.5 Nanoparticle Materials  
Acid capped poly (D,L-lactide-co-glycolide) (PLGA) with a ratio of 75:25 
(lactide:glycolide) was purchased from Evonik (RG 753H). Tween 20 ultrapure (J20605-AP 
Thermo Scientific), triethylammonium formate solution (TEAF) (17901 Honeywell), N,N-
dimethylformamide (DMF) (D119 Fisher Scientific), acetonitrile (ACN) (A955 Fisher Scientific), 
paclitaxel (A4393 APExBIO) and sunitinib malate (sunitinib) (HY-10255 Medchem Express) 
were all used without modification. Additional solvents used were chloroform (C298 Fisher 
Scientific), dimethyl sulfoxide (DMSO) (D1391 Fisher Scientific), 2,2,2-trifluoroethanol (TFE) 
(T63002 Sigma Aldrich) and sodium chloride (NaCl) (S271 Fisher Scientific).  
1 mL Henke-Ject syringes (1481725 Fisher Scientific) and 30-gauge blunt tip industrial 
needles (90130100 CML Supply) were used to electrospray the nanoparticle solution. 9” 
disposable aluminum pie pans (409 Kitchen Dance) were used to collect particles dry and in a 
water bath. 1.5” plastic razor blades (FM053P2 FOSHIO) were used to scrape nanoparticles off 
the aluminum pans following a dry collection. 40 μm nylon mesh cell strainers (22363547 Fisher 
Scientific) were used to filter collected nanoparticle suspensions before centrifuge sorting. 13 mm, 
0.2 μm PTFE syringe filters (09720002 Fisher Scientific) were used for preparing samples for 
liquid chromatography-mass spectrometry. 
3.4.6 Electrospray Fabrication of Nanoparticles 
The drug free, control nanoparticle formulation consisted of 1.96 vol% PLGA, 72.06 vol% 
DMF, 25.00 vol% ACN and 0.98 vol% TEAF. The paclitaxel formulation was 0.39 vol% 





sunitinib solution was composed of 0.32 vol% sunitinib, 1.57 vol% PLGA, 72.11 vol% DMF, 
25.02 vol% ACN and 0.98 vol% TEAF. The combination paclitaxel + sunitinib solution consisted 
of 0.32 vol% sunitinib, 0.39 vol% paclitaxel, 1.57 vol% PLGA, 72.06 vol% DMF, 25.00 vol% 
ACN, 0.98 vol% TEAF. After all components were added together in a glass vial, the solution was 
vortexed before being loaded into a 1 mL syringe with a 30-guage blunt tipped needle. The syringe 
was placed in a KD Scientific syringe pump with a flow rate 0.1 mL/hr. The needle was connected 
to a voltage source and set to 7-10 kV. Below the needle, an aluminum pan was placed for 
collection with a ground plate just underneath. For a dry collection the set up was left as described, 
but for a water bath collection, the ground plate and aluminum pan were placed on a stir plate, 100 
mL of 0.01% Tween 20 in water was placed in the pan and the bath was stirred constantly during 
collection.  
After all the solution had been expelled from the syringe, the particles were collected. For 
a dry collection, the pans were left for ~8 hours in the chemical hood to ensure complete 
evaporation of all solvents. 5 mL of 0.01% Tween 20 in water was pipetted into the pan and a 
plastic razor blade was used to scrape the particles off the aluminum pan while submerged in the 
0.01% Tween 20 puddle. The 0.01% Tween 20 solution would collect the freed particles and the 
particle suspension was then pipetted out of the pan and into a 50 mL centrifuge tube for centrifuge 
sorting. Each pan was thoroughly scraped at least twice to ensure all particles were removed. For 
the water bath collection, after all the solution had been sprayed, the particle suspension was 
simply poured from the pan into two 50 mL centrifuge tubes for centrifuge sorting.  
Once the particles were suspended in 0.01% Tween 20 in 50 mL centrifuge tubes, there no 
longer was a difference between dry and water bath collection. The particle suspension was probe 





minutes at 10,000 x g to pellet particles larger than 1 μm. The supernatant was then carefully 
transferred to a fresh centrifuge without disturbing the pellet of larger particles and centrifuged 
again for 60 minutes at 10,000 x g to pellet all remaining particles in the suspension. After pelleting, 
the supernatant was removed without disturbing the pellet and then the particles were resuspended 
in either water or cell medium for further characterization or use. If there was more than 1 tube for 
a sample then all the samples would be combined, pelleted, and resuspended once more.  
3.4.7 Nanoparticle Characterization  
3.4.7.1 Scanning Electron Microscopy (SEM) 
Nanoparticles imaged with SEM were sprayed directly onto a small silicon chip and then 
sputter coated with gold for 60 seconds. Imaging was on a Tescan Mira3 FEGSEM with a beam 
voltage of 3 kV, a beam energy setting of 6 and a working distance of 5 mm.  
3.4.7.2 Nanoparticle Tracking Analysis (NTA)  
Nanoparticles suspended in water or cell medium were serial diluted between 1 and 4 
orders of magnitude and mixed vigorously. The diluted particle suspension was then analyzed with 
NTA on a Malvern Nanosight NS300 to determine particle size and concentration.  
3.4.7.3 Liquid Chromatography-Mass Spectrometry (LCMS) 
A known number of particles would be pelleted, the supernatant removed, and the particles 
dissolved in ACN with vertexing or sonication. The extracted drug in ACN would then be filtered 
with a 0.2 μm syringe filter and analyzed using an Agilent 6520 Accurate Mass Q-TOF LC/MS 
with a 250 nm wavelength detector. The injection volume was 2 μL with an aqueous solution of 
water and 0.1% formic acid, and an organic solution of 95% ACN, 5% water and 0.1% formic 





pores. Known standard solutions of paclitaxel or sunitinib in ACN were measured with LCMS 







Chapter 4: Investigating the Essential Oil Component, α-terpineol, in a Nanoparticle 
Formulation for an Alternative Chemotherapeutic for Ovarian Cancer  
4.1 Introduction 
The current clinical standard for ovarian cancer therapy consists of surgical de-bulking and 
platinum-based chemotherapy107. However, this treatment has high relapse rates, and a low five 
year survival rate which is attributed to developed chemoresistance and metastasis of the cancer20. 
With a growing interest in testing the effectiveness of alternative cancer therapies, some essential 
oils and their individual, active components have been found to be cytotoxic for cancer cells108. 
Of particular interest is the oil from the Melaleuca alternifolia, or tea tree which has generally 
been explored for its antimicrobial properties. Recent research has demonstrated tea tree oil’s 
ability to cause death in breast cancer cells and mouse mesothelioma while also being less potent 
against non-cancerous cells109,110. This specificity towards killing cancer cells over non-cancerous 
has the potential to make tea tree oil an effective chemotherapeutic. However, there are challenges 
in developing an essential oil as a chemotherapeutic for internal delivery. One is the natural 
variability seen in tea tree oil as it is composed of a variety of components and the ratios of these 
components can change based on the location or year of harvest. Therefore, a single component, 
isolated from the tea tree oil mixture would be more consistent for analysis and use. Another 
challenge in the use of tea tree oil as a chemotherapeutic is the hydrophobicity of the oil which 
requires a form of delivery to increase solubility. To address both challenges, one of the active 





nanoparticle was used to encapsulate αT to create a more effective delivery method. Additionally, 
a conjugation reaction was explored in order to tether the hydroxyl group of the αT to the PLGA 
carboxylic acid end groups in order to create nanoparticle which better encapsulates and stabilizes 
the volatile, small molecule. Together, this was hypothesized to produce a slow-release 
nanoparticle which would be more effective than a simple encapsulation nanoparticle or the free 
αT delivered to ovarian cancer cells.  
4.2 Results and Discussion  
4.2.1 Comparison of αT IC50 Values in Cancerous and Non-cancerous Cells 
To test the suitability of αT as a cancer therapy for ovarian cancer, the IC50 of αT in 
cancerous (OVCAR3) and non-cancerous (HFF and IOSE8) cells was investigated. Cells were 
treated in a 96 well assay and after 24 hours, the number of live and dead cells were counted to 
give a viability percent. The curve was then analyzed with a non-linear fit in Graphpad Prism to 
identify the IC50 for the 3 cell lines. The OVCAR3 IC50 was found to be 466 μM while the non-
cancerous IC50 values were 1.48 mM and 1.25 mM for IOSE8 and HFF, respectively (Figure 4.1). 
This indicates that αT is more specific in killing cancer cells as opposed to non-cancerous and cells 
and has the potential to be used as a chemotherapeutic.  
 
Figure 4.1: IC50 plots of αT 
IC50 plots of A) ovarian cancer cell line OVCAR3, B) non-cancerous ovarian epithelial cell line, 






4.2.2 Investigation of αT-PLGA Conjugation 
αT has a very low solubility in aqueous solutions, and thus a delivery method such as a 
nanoparticle would be needed to deliver αT to internal cancers. However, as αT has a very low 
molecular weight (~154 g/mol) and is highly volatile, it is presumed that simply encapsulating αT 
within a polymer nanoparticle will not be very effective as αT will evaporate or diffuse very 
quickly. Therefore, two methods of tethering the αT to the carboxylic acid end groups of PLGA 
were investigated with the goal of creating a slow-release formulation of an αT loaded nanoparticle 
(Figure 4.2).  
 
Figure 4.2: Schematic of PLGA nanoparticles designed to encapsulate αT for cancer therapy 
A) Schematic of αT tethered to the acid end groups of PLGA. B) Schematic of the control 
nanoparticle without any αT. C) Schematic of a nanoparticle with free αT encapsulated in a PLGA 
nanoparticle. D) Nanoparticle fabricated out of the conjugated PLGA+αT polymer shown in (A). 
E) Nanoparticle fabricated out of conjugated PLGA+αT and encapsulating free αT.  
 
Two methods were investigated to tether the αT to the carboxylic acid end groups of the 
PLGA chain, one used an isocyanate linker, isophorone diisocyanate (IPDI), between the PLGA 





PLGA through esterification (Figure 4.3C). IPDI is a bifunctional isocyanate and depending on 
the catalyst, one isocyanate functional group will be more reactive than the other, and by testing 
different time points, identification of the time needed to bond the more reactive isocyanate can 
be found (Figure 4.3A). Step two would then be completed as a second reaction and would need 
to be reacted for longer to ensure that the more unreactive isocyanate arm reacts with αT (Figure 
4.3B).   
 
Figure 4.3: Reaction Schemes for tethering αT to PLGA 
The two-step isocyanate linker reaction starts with A) reacting IPDI to the carboxylic acid end 
groups on the PLGA and B) the second step reacts the hydroxyl on the αT to the remaining 
isocyanate group on the IPDI. C) The singe step esterification reaction between the PLGA 






The first step of the IPDI reaction was carried out under at 35°C with three different 
catalysts at various time points and analyzed with attenuated total reflection-infrared (ATR-IR) 
(Figure 4.4) and gel permeation chromatography (GPC) (Table 4.1). ATR-IR allowed for the 
identification of the IPDI bonding to the PLGA with the appearance of the isocyanate peak at 2260 
and the amine peak at 3340 (dotted lines in Figure 4.4). As a negative control, no catalyst was first 
investigated and evidence of an amine and an isocyanate peak were seen with ATR-IR at 7 days 
(Figure 4.4A), however, the molecular weight of the polymer after 7 days of reaction (74.1 kDa) 
is more than double that of unreacted PLGA (33.7 kDa). This indicates that chain to chain reaction 
of PLGA with the IPDI linker occurs with a high frequency without the use of a catalyst.  
Di-n-butyltin dilaurate (DBTL) was the first catalyst investigated as it is the most 
commonly used catalyst with IPDI reactions, and has shown a high selectivity for the secondary 
isocyanate carbon111,112. The amine and isocyanate peaks appear within 4 hours when DBTL is 
used (Figure 4.4B), however within 4 hours the molecular weight has also increased by ~5 kDa 
and continues to slowly increase as the time of reaction also increases. This large increase in 
molecular weight was unexpected as the molecular weight of IPDI is ~222 Da and an increase of 
~444 Da (2 IPDI per PLGA chain) would be within the error of the GPC. Further investigation of 
DBTL’s mechanism of reaction revealed a carboxylic acid substitution (Figure 4.5) which could 
easily lead to DBTL linking PLGA chains together and causing an increase in the average 
molecular weight despite its previous use with carboxylic acid reactants113,114.  
Triethylamine (TEA) was investigated as an alternative catalyst to DBTL, and with TEA, 
the primary isocyanate is more reactive115. The TEA reaction is slower than the DBTL reaction as 
evidenced by the isocyanate peak requiring 24 hours to reach the same intensity as 4 hours with 





bond and is due to TEA which was ineffectually removed during the polymer wash steps. The 
molecular weight of the reacted polymer also increases with TEA as the catalyst (Table 4.1). 
Another alternative to DBTL which was tested was magnesium chloride hexahydrate (MgCl2) as 
it had been shown to improve reaction selectively with sterically hindered carboxylic acids114. 
Within the system tested here however, the isocyanate peak did not increase over a reaction time 
of 24 hours and a broad amine peak formed which suggested the formation of a byproduct instead 
of the PLGA-IPDI compound (Figure 4.4D). Additionally, the molecular weight increase seen in 






Figure 4.4: ATR-IR spectra of the region of interest for the PLGA+IPDI reaction 
Spectra resulting from the reaction of PLGA and IPDI A) without a catalyst for 72 hours and 7 
days, B) with DBTL as the catalyst over a range of 4 to 12 hours, C) with TEA as the catalyst over 
a range of 12 to 24 hours, and D) with MgCl2 as the catalyst at 3 and 24 hours. Dotted lines are at 
the location of the amine at 3340 and the isocyanate at 2260 which appear when the reaction has 
occurred.  
 
Table 4.1: PLGA molecular weights measured with GPC  
Catalyst Time (hrs) MW (kDa) PDI 





None 72 37.2 1.85 
None 168 74.1 2.13 
DBTL 4 42.2 1.76 
DBTL 6 40.8 1.76 
DBTL 8 44.0 1.95 
DBTL 10 46.1 1.92 
DBTL 12 45.2 1.95 
TEA 12 42.9 1.95 
TEA 16 42.7 2.08 
TEA 24 44.1 2.14 
MgCl2 3 54.3 1.88 
MgCl2 24 76.5 2.21 
 
 
Figure 4.5: Suggested reaction scheme for DBTL reacting to two PLGA chains 
 
With the catalysts tested, a high enough isocyanate selectivity was not achieved to prevent 
PLGA from linking to itself and so the second method of esterification was investigated (Figure 
4.3C). Two different types of catalyst were tested: 1) tosylation, which functionalizes the αT 
hydroxyl, and 2) metallic catalysts which functionalize the PLGA carboxylic acid116,117. Tosylation 
used p-toluenesulfonyl chloride as the catalyst and pyridine as the solvent, while the metallic 





(Al(NO3)3) and zinc nitrate hexahydrate (Zn(NO3)2). Following the reactions, the polymer was 
washed and dried and then characterized with ATR-IR (Figure 4.6) and GPC (Table 4.2). Spectra 
obtained from ATR-IR were analyzed for peak formation at 1675 due to the presence of the αT 
alkene and the reduction of the 1425 PLGA carboxylic acid peak from esterification. Of the 
catalysts tested, none showed a reduction in the carboxylic acid peak intensity suggesting that the 
reaction did not occur despite the alkene peak formation with the Fe(NO3)3 and Al(NO3)3 catalysts 
(Figure 4.6). The alkene peak formation with these two catalysts is thought to be a byproduct of 
the reaction as there was no corresponding αT hydroxyl peak at 3370 (data not shown). GPC 
measurements of molecular weight (Table 4.2) show that all reactions cause a reduction in PLGA 
molecular weight indicating that the reaction conditions favored the breaking of ester bonds as 
opposed to the formation. The Al(NO3)3 reaction did not show a reduction in molecular weight 
after a 3 hour reaction but did after 5 hours. The ATR-IR spectra at 3 hours (Figure 4.6) and 5 
hours (not shown) were identical and did not indicate that the reaction had occurred.  
 
Figure 4.6: ATR-IR spectra of 4 esterification catalyzed reactions of PLGA and αT 







Table 4.2: GPC measured molecular weight of PLGA following PLGA+αT esterification reactions 
Catalyst Time (hrs) MW (kDa) PDI 
– – 33.7 1.83 
TsCl 3 30.5 1.93 
Al(NO3)3 3 33.9 1.99 
Al(NO3)3 5 23.9 1.98 
Zn(NO3)2 3 28.2 2.00 
Fe(NO3)3 3 11.8 1.82 
 
As none of the reaction schemes, IPDI linker or esterification, tested up to this point yielded 
a complete reaction without effecting the PLGA molecular weight, PLGA nanoparticles were 
fabricated without using a conjugated PLGA-αT polymer.  
4.2.3 Nanoparticle Characterization 
PLGA nanoparticles were fabricated in the same method as described in Chapter 3. Briefly, 
an electrospray method was optimized for solvent composition, spray parameters and the 
collection method as it was found that the stirring water bath would extend wet droplets into fiber-
like particles. Thus, a dry collection method was used for the αT nanoparticles as well. Imaging of 
the nanoparticles with scanning electron microscopy (SEM) was carried out by placing a small 
silicon chip under the electrospray for ~3 hours and then imaging (Figure 4.7A, B). After spraying 
3 batches of both control and αT loaded nanoparticles, the nanoparticles were collected from the 
aluminum pans, sorted using centrifugation and then their size and concentration was measured 
using nanoparticle tracking analysis (NTA) (Figure 4.7C, D). Loading of αT in the nanoparticles 
was measured by taking a known number of nanoparticles and dissolving them in acetonitrile. The 
extracted αT was then measured using liquid chromatography-mass spectrometry (LCMS) against 





nanoparticles are listed in Table 4.3. The control and αT nanoparticles were of similar sizes and 
through LCMS, it was confirmed that the electrosprayed PLGA nanoparticles could be used to 
encapsulate αT. However, the fabrication rate and αT loading were very low and the production 
time required to have enough nanoparticles of a simple in vitro viability assay would be about 63 
hours of continuous production. Therefore, the effect of delivering αT via nanoparticle was not 
investigated at this time. 
 
Figure 4.7: Characterization of αT loaded PLGA nanoparticles 
A) SEM image of αT nanoparticles. B) NTA size histogram of αT nanoparticles. C) Known 
standard calibration curve of αT for LCMS measurements of αT loading. D) SEM image of control 
nanoparticles. E) NTA size histogram of control nanoparticles.  
 










αT 159 ± 22 201 ± 78 1.65 x 109 2.54 x 10-10 






4.2.4 In vitro OVCAR3 αT Viability   
Without a method to tether αT to the PLGA carboxylic acid end groups, and with the 
extensive amount of time required to fabricate enough αT loaded nanoparticles, only free αT was 
delivered to OVCAR3 cells in a 3D viability in vitro assay. OVCAR3 were plated in 20 μL droplets 
on a 384-hanging drop plate with 100 cells/droplet. The spheroids were cultured for 5 days (Figure 
4.8A) and then treated with 500 μM αT or served as the control (Figure 4.8B, C). After 2 days of 
treatment, cell viability was measured with an MTS assay (Figure 4.8D). Significant death was 
seen in the 500 μM αT treated condition and the treated spheroids were smaller than the control 
spheroids. This suggests that αT could be used as a chemotherapeutic for ovarian cancer.  
 
Figure 4.8: in vitro evaluation of OVCAR3 treated with free αT in a 3D hanging drop model 
Optical microscopy images of A) OVCAR3 spheroid on day 5, B) control spheroid imaged on day 
7, C) spheroid treated with 500 μM αT imaged on day 7. D) Viability results of control spheroids 
compared to those treated with 500 μM αT (N = 3, *p<0.05).  
 
4.3 Conclusions  
One of the active components of tea tree oil, α-terpineol (αT), has been shown to be a 
potential cancer therapy for ovarian cancer. When comparing the IC50 value between cancerous 
and non-cancerous cells, ovarian cancer cells had an IC50 of about half that of non-cancerous cells 
indicating an inherent specificity in αT. Additionally, in a physiologically relevant 3D in vitro 
assay, significant death was seen when OVCAR3 were treated with 500 μM αT. It was 





the solubility and deliverability of αT for internal cancers. Electrosprayed PLGA nanoparticles 
were fabricated encapsulating αT, and the αT loaded nanoparticles were comparable in size and 
morphology to control nanoparticles. However, electrospray fabrication has a low production rate, 
and this led to a time restriction in producing enough nanoparticles to conduct a 3D in vitro assay 
comparing αT nanoparticles and free αT, and so this has not been investigated yet. Lastly, it was 
hypothesized that conjugation of the αT to the carboxylic acid end groups of PLGA would create 
a stabilizing effect on the encapsulated αT, thus creating a slow-release formulation with a higher 
initial loading. Two reaction methods were explored, an isocyanate linker and esterification, 
however, neither method resulted in a completed reaction that did not also alter the molecular 
weight of the PLGA. Therefore, the effect of αT stabilization within the PLGA nanoparticle was 
not explored at this time. Future work focused on the scale-up of electrospray nanoparticle 
fabrication similar to Chapter 3 could be used to produce enough αT loaded nanoparticles for in 
vitro studies. Additionally, alternate essential oils could be tested for cancer cell cytotoxicity and 
in synthesizing a PLGA-essential oil conjugated polymer for a slow-release nanoparticle.  
4.4 Materials and Methods 
4.4.1 Cell Culture and Materials 
Epithelial ovarian cancer cells, OVCAR3 (American Type Culture Collection), as well as 
non-cancerous cells, HHF (fibroblasts) and IOSE8 (ovarian epithelial) were maintained in 2D 
growth culture in Gibco RMPI 1640 cell medium with L-glutamine and phenol red, supplemented 
with 10% fetal bovine serum and 5% Gibco antibiotic-antimycolic (100x). The MTS assay was 
purchased from Abcam and the manufacturer protocols followed. 
2D culture analysis was in a 96 well plate with 500 cells/well with a maximum volume of 





counted and seeded. Cells were allowed to settle overnight and then treated the following day. 
After 24 hours of treatment, both live and dead cells were collected from the wells and counted 
with trypan blue on a hemocytometer to obtain a viability percent.  
To plate in a 384 hanging drop well plate for 3D culture, OVCAR3 were removed from 
2D growth culture with Gibco 0.25% Trypsin–EDTA (1x). After counting, the cells were 
resuspended in the proper dilutions and plated in 20 µL droplets with 100 cells per droplet. 
Spheroids were cultured for 5 days with imaging and feeding on day 3. On day 5, the spheroids 
were imaged again, and drug treated. Drug incubation lasted for 2 days, and on day 7 the different 
conditions were imaged a final time and then the cell viability was measured with an MTS assay.  
4.4.2 2D IC50 Quantification 
Determination of the IC50 value of αT for OVCAR3 and 2 non-cancerous cell lines was 
conducted in 2D. Cells were plated at 500 cells/well and the cells allowed to settle overnight. The 
next day, αT was delivered over a range of 60 μM to 60 mM and after 24 hours the number of live 
and dead cells was counted using trypan blue on a hemocytometer. Identification of the IC50 was 
done using a non-liner fit in Graphpad Prism 9.0.0.  
4.4.3 3D Cell Viability Assay 
On day 7 of the 3D viability assay, 2 μL of the MTS reagent was added to each well and 
the plate incubated for 4 hours and then read on a BioTek Synergy HT microplate reader. Analysis 
of the data was then carried out in Graphpad Prism 9.0.0.  
4.4.4 Nanoparticle Materials  
Acid capped poly (D,L-lactide-co-glycolide) (PLGA) with a ratio of 75:25 
(lactide:glycolide) was purchased from Evonik (RG 753H). Tween 20 ultrapure (J20605-AP 





dimethylformamide (DMF) (D119 Fisher Scientific), acetonitrile (ACN) (A955 Fisher Scientific), 
and α-terpineol (αT) (W304522 Sigma-Aldrich) were all used without modification.  
1 mL Henke-Ject syringes (1481725 Fisher Scientific) and 30-gauge blunt tip industrial 
needles (90130100 CML Supply) were used to electrospray the nanoparticle solution. 9” 
disposable aluminum pie pans (409 Kitchen Dance) were used to collect particles. 1.5” plastic 
razor blades (FM053P2 FOSHIO) were used to scrape nanoparticles off the aluminum pans. 40 
μm nylon mesh cell strainers (22363547 Fisher Scientific) were used to filter collected 
nanoparticle suspensions before centrifuge sorting. 13 mm, 0.2 μm PTFE syringe filters (09720002 
Fisher Scientific) were used for preparing samples for liquid chromatography-mass spectrometry. 
4.4.5 Electrospray Fabrication of Nanoparticles 
The drug free, control nanoparticle formulation consisted of 1.96 vol% PLGA, 72.06 vol% 
DMF, 25.00 vol% ACN and 0.98 vol% TEAF. The αT formulation was 3.79 vol% αT, 1.52 vol% 
PLGA, 69.60 vol% DMF, 24.15 vol% ACN and 0.95 vol% TEAF. After all components were 
added together in a glass vial, the solution was vortexed before being loaded into a 1 mL syringe 
with a 30-guage blunt tipped needle. The syringe was placed in a KD Scientific syringe pump with 
a flow rate 0.1 mL/hr. The needle was connected to a voltage source and set to 7-10 kV. Below 
the needle, an aluminum pan was placed for collection with a ground plate just underneath.  
After all the solution had been expelled from the syringe, the particles were left for ~8 
hours in the chemical hood to ensure complete evaporation of all solvents. The particles were then 
collected by pipetting 5 mL of 0.01% Tween 20 in water into the pan and a plastic razor blade was 
used to scrape the particles off the aluminum pan while submerged in the 0.01% Tween 20 puddle. 





then be pipetted out of the pan and into a 50 mL centrifuge tube for centrifuge sorting. Each pan 
would be thoroughly scraped at least twice to ensure all particles were removed.  
Once the particles were suspended in 0.01% Tween 20, the particle suspension would be 
probe sonicated, poured through a 40 μm filter to remove large aggregates and then centrifuged 
for 15 minutes at 10,000 x g to pellet particles larger than 1 μm. The supernatant was then carefully 
transferred to a fresh centrifuge without disturbing the pellet of larger particles and centrifuged 
again for 60 minutes at 10,000 x g to pellet all remaining particles in the suspension. After pelleting, 
the supernatant was removed without disturbing the pellet and then the particles were resuspended 
in either water or cell medium for further characterization or use. If there was more than 1 tube for 
a sample then all the samples were combined, pelleted, and resuspended once more.  
4.4.6 Nanoparticle Characterization 
4.4.6.1 Scanning Electron Microscopy (SEM) 
Nanoparticles imaged with SEM were sprayed directly onto a small silicon chip and then 
sputter coated with gold for 60 seconds. Imaging was on a Tescan Mira3 FEGSEM with a beam 
voltage of 3 kV, a beam energy setting of 6 and a working distance of 5 mm.  
4.4.6.2 Nanoparticle Tracking Analysis (NTA) 
Nanoparticles suspended in water or cell medium were serial diluted between 1 and 4 
orders of magnitude and mixed vigorously. The diluted particle suspension was then analyzed with 
NTA on a Malvern Nanosight NS300 to determine particle size and concentration.  
4.4.6.3 Liquid Chromatography-Mass Spectrometry (LCMS) 
A known number of particles would be pelleted, the supernatant removed, and the particles 
dissolved in ACN with vertexing or sonication. The extracted drug in ACN would then be filtered 





with a 250 nm wavelength detector. The injection volume was 2 μL with an aqueous solution of 
water and 0.1% formic acid, and an organic solution of 95% ACN, 5% water and 0.1% formic 
acid. The column was an Agilent Zorbax Eclipse Plus C18 (959757-902), 2.1 x 50 mm with 1.8 μm 
pores. Known standard solutions of αT in ACN were measured with LCMS first to create a 
calibration curve which the unknown nanoparticle sample could then be compared to.  
4.4.7 αT+PLGA Conjugation Materials  
Acid capped poly (D,L-lactide-co-glycolide) (PLGA) with a ratio of 75:25 
(lactide:glycolide) was purchased from Evonik (RG 753H). N,N-dimethylformamide (DMF) 
(D119 Fisher Scientific), acetonitrile (ACN) (A955 Fisher Scientific), dichloromethane (DCM) 
(D37 Fisher Scientific), hexane (H302 Fisher Scientific), pyridine (P368 Fisher Scientific), 
isophorone diisocyanate (IPDI) (317624 Aldrich Chemistry), tetrahydrofuran (THF) (T397 Fisher 
Scientific), triethylamine (TEA) (157911000 ARCOS Organics), di-n-butyltin dilaurate (DBTL) 
(71130 Alfa Aesar), p-toluenesulfonyl chloride (TsCl) (T0272 TCI), iron (III) nitrate nonahydrate 
(Fe(NO3)3) (216828 Sigma-Aldrich), aluminum nitrate nonahydrate (Al(NO3)3) (AC218281000 
ARCOS Organics), Zinc nitrate hexahydrate (Zn(NO3)2) (228737 Sigma-Aldrich), aluminum 
chloride hexahydrate (AlCl3) (237078 Sigma-Aldrich), calcium chloride dihydrate (CaCl2) (BP510 
Fisher Scientific), magnesium chloride hexahydrate (MgCl2) (M33 Fisher Scientific) and α-
terpineol (αT) (W304522 Sigma-Aldrich) were all used without modification 
4.4.8 αT+PLGA Reaction Schemes 
4.4.8.1 Isocyanate Linker Schemes 
No Catalyst – 88.2 wt% PLGA was dissolved in 11.7 wt% DCM and 0.1 wt% IPDI was 
added to a 100 mL round bottom flask with a stir bar. The reaction was heated in a heat jacket with 





halted by crashing the solution in hexane at a concentration of 12.5 vol% or less in a 50 mL 
centrifuge tube. The crashed solution was then centrifuged for 2 minutes at 10,000 x g to pellet the 
polymer. The supernatant was removed, and the polymer was dried under vacuum. Once dry, the 
polymer was dissolved in DCM at about 2% w/v, and if there were multiple tubes of the same 
polymer, they were combined at this step. The polymer solution was then washed again by crashing 
at ~12.5 vol% in hexane, centrifuged for 2 minutes at 10,000 x g, the supernatant removed, and 
the polymer dried under vacuum. 
DBTL Catalyst – 88.1 wt% PLGA was dissolved in 11.7 wt% DCM and 0.1 wt% IPDI and 
DBTL were added to a 100 mL round bottom flask with a stir bar. The reaction was heated in a 
heat jacket with a variable outlet to 35°C and reacted for the desired amount of time. When done, 
the reaction was halted by crashing the solution in hexane at a concentration of 12.5 vol% or less 
in a 50 mL centrifuge tube. The crashed solution was then centrifuged for 2 minutes at 10,000 x g 
to pellet the polymer. The supernatant was removed, and the polymer was dried under vacuum. 
Once dry, the polymer was dissolved in DCM at about 2% w/v, and if there were multiple tubes 
of the same polymer, they were combined at this step. The polymer solution was then washed 
again by crashing at ~12.5 vol% in hexane, centrifuged for 2 minutes at 10,000 x g, the supernatant 
removed, and the polymer dried under vacuum. 
TEA Catalyst – 88.1 wt% PLGA was dissolved in 11.7 wt% DCM and 0.1 wt% IPDI and 
TEA were added to a 100 mL round bottom flask with a stir bar. The reaction was heated in a heat 
jacket with a variable outlet to 35°C and reacted for the desired amount of time. When done, the 
reaction was halted by crashing the solution in hexane at a concentration of 12.5 vol% or less in a 
50 mL centrifuge tube. The crashed solution was then centrifuged for 2 minutes at 10,000 x g to 





dry, the polymer was dissolved in DCM at about 2% w/v, and if there were multiple tubes of the 
same polymer, they were combined at this step. The polymer solution was then washed again by 
crashing at ~12.5 vol% in hexane, centrifuged for 2 minutes at 10,000 x g, the supernatant removed, 
and the polymer dried under vacuum. 
MgCl2 – 75.0 wt% PLGA was dissolved in 10.0 wt% DCM and 0.1 wt% IPDI and 15.0 
wt% MgCl2 were added to a 100 mL round bottom flask with a stir bar. The reaction was heated 
in a heat jacket with a variable outlet to 35°C and reacted for the desired amount of time. When 
done, the reaction was halted by crashing the solution in hexane at a concentration of 12.5 vol% 
or less in a 50 mL centrifuge tube. The crashed solution was then centrifuged for 2 minutes at 
10,000 x g to pellet the polymer. The supernatant was removed, and the polymer was dried under 
vacuum. Once dry, the polymer was dissolved in DCM at about 2% w/v, and if there were multiple 
tubes of the same polymer, they were combined at this step. The polymer solution was then washed 
again by crashing at ~12.5 vol% in hexane, centrifuged for 2 minutes at 10,000 x g, the supernatant 
removed, and the polymer dried under vacuum. 
Esterification Schemes 
TsCl – 62.4 wt% PLGA and 31.2 wt% TsCl were dissolved in 5.5 wt% pyridine and 1.0 
wt% αT in a glass vial with a stir bar. The reaction was heated in a sand bath to 65°C and stirred 
for 3 hours. After 3 hours, the reaction was halted by crashing the solution in hexane at a 
concentration of 12.5 vol% or less in a 50 mL centrifuge tube. The crashed solution was then 
centrifuged for 2 minutes at 10,000 x g to pellet the polymer. The supernatant was removed, and 
the polymer was dried under vacuum. Once dry, the polymer was dissolved in DCM at about 2% 





polymer solution was then washed again by crashing at ~12.5 vol% in hexane, centrifuged for 2 
minutes at 10,000 x g, the supernatant removed, and the polymer dried under vacuum. 
Al(NO3)3 – 44.7 wt% PLGA and 50.8 wt% Al(NO3)3 were dissolved in 3.8 wt% DMF with 
0.7 wt% αT in a glass vial with a stir bar. After 3 hours, the reaction was halted by crashing the 
solution in cold water at a concentration of 12.5 vol% or less in a 50 mL centrifuge tube. The 
crashed solution was then centrifuged for 30 minutes at 10,000 x g to pellet the polymer. The 
supernatant was removed, and the polymer was dissolved in DCM at about 2% w/v, and if there 
were multiple tubes of the same polymer, they were combined at this step. The polymer solution 
was then washed again by crashing at ~12.5 vol% in hexane, centrifuged for 2 minutes at 10,000 
x g, the supernatant removed, and the polymer dried under vacuum. 
 Zn(NO3)2 – 50.0 wt% PLGA and 45.0 wt% Zn(NO3)2 were dissolved in 4.2 wt% DMF 
with 0.8 wt% αT in a glass vial with a stir bar. After 3 hours, the reaction was halted by crashing 
the solution in cold water at a concentration of 12.5 vol% or less in a 50 mL centrifuge tube. The 
crashed solution was then centrifuged for 30 minutes at 10,000 x g to pellet the polymer. The 
supernatant was removed, and the polymer was dissolved in DCM at about 2% w/v, and if there 
were multiple tubes of the same polymer, they were combined at this step. The polymer solution 
was then washed again by crashing at ~12.5 vol% in hexane, centrifuged for 2 minutes at 10,000 
x g, the supernatant removed, and the polymer dried under vacuum. 
Fe(NO3)3 – 43.0 wt% PLGA and 52.7 wt% Fe(NO3)3 were dissolved in 3.7 wt% DMF with 
0.7 wt% αT in a glass vial with a stir bar. After 3 hours, the reaction was halted by crashing the 
solution in cold water at a concentration of 12.5 vol% or less in a 50 mL centrifuge tube. The 
crashed solution was then centrifuged for 30 minutes at 10,000 x g to pellet the polymer. The 





were multiple tubes of the same polymer, they were combined at this step. The polymer solution 
was then washed again by crashing at ~12.5 vol% in hexane, centrifuged for 2 minutes at 10,000 
x g, the supernatant removed, and the polymer dried under vacuum. 
4.4.9 αT+PLGA Conjugation Characterization  
4.4.9.1 Attenuated Total Reflection-Infrared (ATR-IR) Spectroscopy 
Once the polymer had been washed and dried under vacuum, a ~10 mg piece of the polymer 
was removed and analyzed using ATR-IR on a Thermo-Nicolet IS-50 with a diamond crystal over 
a range of 4000 cm2 to 400 cm2. Spectra were then normalized and analyzed for changes in peaks 
at points of interest based on which reaction scheme was being used.  
4.4.9.2 Gel Permeation Chromatography (GPC) 
After the polymer was washed and dried, a small piece would be dissolved at a 
concentration of 10% w/v in THF and filtered through a 0.45 μm PVDF syringe filter. The 









Chapter 5: Conclusions and Future Directions 
This work was focused on designing polymer nanoparticles which would improve 
treatment options for ovarian cancer. The development and exploration of the wettability 
engendered templated self-assembly (WETS) method aimed to enable the undertaking of a 
systematic study of nanoparticle properties. By manufacturing nanoparticles with the same method 
and a systematic range of properties, studies of nanoparticle biodistributions, circulation half-lives 
and efficacy could be studied. This would increase the general understanding of nanoparticle drug 
delivery for the field, not just ovarian cancer. Co-delivery of drugs using a nanoparticle was studied 
as a method to treat ovarian cancer holistically. Cancer stem cells (CSC) dynamically interact with 
non-cancerous cells in their environment, and many of these interactions increase the malignancy 
of the cancer. Platelet derived growth factor (PDGF) was previously identified as a communication 
pathway between ovarian CSC and mesenchymal stem cells (MSC) which was implicated in 
higher CSC chemoresistance, ALDH activity and migration potential. Sunitinib, a tyrosine kinase 
inhibitor, was suggested as a potential treatment to stop this communication. PLGA nanoparticles 
encapsulating paclitaxel and sunitinib were electrosprayed and characterized in order to create a 
co-delivery nanoparticle which would be effective in reducing the effect that PDGF mediated MSC 
support would have on CSC. The nanoparticles could encapsulate both paclitaxel and sunitinib 
and were ~150-200 nm in diameter. Additionally, the effect of paclitaxel and sunitinib delivered 
in a 3D hanging drop in vitro model was investigated and found small trends suggesting that co-





encapsulate α-terpineol (αT), one of the active components of tea tree oil. αT has been shown to 
be more selective in killing cancerous cells than non-cancerous cells in ovarian cancer and when 
delivered as a free oil in vitro, caused significant death in OVCAR3. Electrosprayed nanoparticles 
can encapsulate αT which would increase the solubility and deliverability of the volatile, small 
molecule, however investigations to develop a method to conjugate αT to the PLGA carboxylic 
acid end groups were not successful. 
5.1 WETS Future Directions  
Drawbacks in the WETS method that were identified include: 1) the non-wetting, 
fluorinated silane was found to permit nanoscale fouling which rendered the background wettable 
on large scale substrates, 2) fabrication of nanoscale WETS substrates is difficult and 3) scale-up 
of WETS particle production needs to be greatly increased. Future work on WETS will need to 
focus on solving these issues as production will be extremely slow or impossible unless all three 
are addressed. 
The fluorinated silane used in this work will need to be replaced completely with a silane 
that does not foul upon submersion in a polymer solution and can also fit within the existing WETS 
substrate lithography method. Suggested silanes to try include 1,3-PDMS, monochloro-flourinated 
silanes, and alkyl silanes as these silanes have shown promising contact angles and can be 
deposited using chemical vapor deposition. If the silane does not cleave from TiO2 upon exposure 
to UV, the photoresist pattern will need to be reversed and patterned on a blanket of TiO2. This 
method will be similar to the original WETS substrate fabrication except that the photomask 
pattern will need to be inverted, or the photoresist will need to undergo an image reversal protocol. 
Once the photoresist has been developed on a blanket of TiO2, the substrate domains will be 





wetting background, then remove the photoresist to reveal the domains and expose to UV to make 
them wettable.  
In order to optimize the stepper protocol to consistently fabricate nanoparticles with WETS, 
new masks will need to be designed with the appropriate guiding marks for a stepper. However, 
due to the photoresist and TiO2 patterning, these guiding marks will also pattern polymer particles 
after dip-coating and steps will need to be taken to either remove the guiding marks before dip-
coating or the larger particles will need to be removed after dip-coating. As the wettable domain 
gets smaller, the release layer will probably need to become thicker to ensure complete collection 
of the particles from the substrate.  
Scale-up of WETS production will require larger substrates, however the cleanroom at the 
University of Michigan cannot support 6-inch or 12-inch wafers which would be the first next step. 
A collaboration with a cleanroom with larger capabilities might be possible if the stepper and 
silane protocols are finalized. Another method of scale up would be dip-coating multiple substrates 
at the same time into a larger polymer solution container, however the substrates faces would need 
to be held more than 2lc apart in order to ensure that the solution recedes from all the substrates. 
One other method of scale-up would be to develop a roll-to-roll process similar to what is used by 
the particle replication in non-wetting templates (PRINT) technology72,118. 
 With the WETS method currently, investigation into other applications such as biological 
sensors, optical devices, nanomotors and self-assembly could be beneficial. These uses might 
require fewer and larger particles which WETS is currently capable of.  
5.2 Co-delivery Nanoparticles Future Directions 
The limitation of slow fabrication is also present in electrospraying, however not as much 





construction of ~7 more electrospray stations which can all be run in parallel to fabricate particles. 
A multiplex electrospray system, one with multiple needle outlets could be used to increase the 
rate of production at a single station105. The multiplex needle might need to be custom built and 
then would also require more frequent changes of the collection pan. An ideal set up would have 
a multiplex spray with a large solution syringe that sprayed onto a slow-moving conveyor belt for 
collection. This system would need a stable spray, but then could run without monitoring overnight 
or for a day to produce more particles easily. Two syringes on the same syringe pump, to roughly 
model a multiplex spray, was attempted, however the spray was not stable either due to each needle 
needing its own voltage source or the needles being too close together. An emulsion (much higher 
production yield) could also be tested to see if both drugs can be encapsulated, however removal 
of the poly(vinyl alcohol) emulsifier is extremely difficult which leads to particles that are ‘glued’ 
together after freeze drying. With an increase in nanoparticle fabrication, cell studies can be 
undertaken to study the efficacy of co-delivery.  
Future work for the 3D hanging drop model needs to investigate the differences between 
the work here and that done previously in our lab3. One difference is the number of cells/well, 
where previously 12 cells/well were tested and in this work 400 cells/well were used in order to 
conduct experiments in a shorter time frame. The ratio (1:3) of CSC to MSC was maintained, but 
the large change in number of cells could have some effect and might be worth investigating. 
Another difficulty was the slow rate at which MSC grow and the ease with which they die 
compared to the CSC. One method of addressing this could be do use MSC condition media instead 
of a co-culture. Cell-cell connections and reciprocal signaling will be removed from the culture 






5.3 α-terpineol Nanoparticle Future Directions 
Increased production of electrosprayed nanoparticles outlined in section 5.2 is also 
applicable to increasing the production of αT loaded nanoparticles for this work. Additionally the 
encapsulation of other essential oil components could be used for many applications other than 
cancer drug delivery including antimicrobial uses, cosmetics, antivirals, and antioxidants119–122.  
Further investigation of reaction schemes for a conjugated PLGA+αT could also look at other 
essential oil components such as perillyl alcohol as they may be better candidates for reacting. 
Perillyl alcohol was also tested against non-cancerous and ovarian cancer cells and was found to 
be more toxic towards non-cancerous cells so it was not fully investigated for conjugation. Future 
work on αT as a chemotherapeutic would need to explore and consider other factors such as 
metabolism, biodistribution, developed drug resistance and in vivo toxicity limit which could make 
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